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Chlamydia pneumoniae is an obligate intracellular human pathogen whose primary site 
of infection is the respiratory tract. In addition to respiratory tract infections, such as 
sinusitis and pharyngitis, C. pneumoniae has been related to several chronic 
inflammatory diseases of which atherosclerosis is the most widely studied. In order to 
contribute to the pathogenesis e.g. in atheromatous arteries, C. pneumoniae must 
disseminate from lungs to other tissues. This translocation occurs via peripheral blood 
mononuclear cells (PBMCs), mainly monocytes and macrophages. The presence of C. 
pneumoniae has been reported to induce inflammatory molecule production and alter 
redox balance in these cells, while also promoting their foam cell formation, migration 
and adherence. The ability of C. pneumoniae to persist inside the PBMCs, and thus 
become refractory to conventional antibiotics complicates the management of the 
associated underlying infection in chronic inflammatory diseases. Most C. pneumoniae 
susceptibility studies are currently based on the use of permissive cell lines, such as 
epithelial and endothelial cell lines in which the bacteria are actively replicating, which 
leaves the persistent infections unnoticed. Therefore, in addition to new active 
compounds against C. pneumoniae, new methods to study their effects against the 
persistent chlamydial infection are urgently needed. 
In this study, dibenzocyclooctadiene lignans, new antichlamydial compounds 
originating from berries of medicinal plant, Schisandra chinensis, were profiled 
regarding different aspects of C. pneumoniae-PBMC interactions. Human THP-1, a 
monocyte and macrophage cell line, and a murine macrophage cell line RAW264.7 were 
used in the studies to examine the effects of the schisandrin lignans on C. pneumoniae 
infection and their influence on host cell responses. 
Oxidative stress is the basic pathological mechanism underlying a spectrum of chronic 
inflammatory diseases, and it largely contributes to the consequences of C. pneumoniae 
infection as well. In this work, C. pneumoniae was found to induce proinflammatory 
cytokine, interleukin (IL)-12 secretion in the human monocytic cell line. It also increased 
 
 
the intracellular reactive oxygen species (ROS) and nitric oxide (NO) levels in 
macrophages, and it had an impact on the concentration of glutathione (GSH), the major 
small-molecule antioxidant, in macrophages. Gene expression analysis of murine 
macrophages revealed that C. pneumoniae suppressed the peroxisome proliferator-
activated receptor γ (PPARγ) transcription in the cells, which influences lipid 
metabolism and inflammatory responses in these cells. 
Schisandrin lignans had an impact on C. pneumoniae-induced alterations in these cell 
models. Schisandrin B and schisandrin C reduced the elevated interleukin (IL) -12 
cytokine levels, as well as the LPS induced IL-6 and IL-12 levels. Schisandrin lignans 
also affected cellular oxidative balance by elevating the basal ROS levels while 
simultaneously reducing the ROS or NO levels induced by infection or LPS. The redox 
balance alteration was also shown within the GSH levels, which were reduced by the 
lignans in THP-1 monocytes and macrophages but elevated in RAW264.7 cells. 
Schisandrin B additionally upregulated the transcription of genes involved in GSH 
synthesis, GCL and GGT-1. Schisandrin B and schisandrin C also reduced the C. 
pneumoniae-induced macrophage foam cell formation and altered the related expression 
of PPARγ and ABCA1 genes. 
In this work, a new platform for studying the C. pneumoniae transfer between lung 
epithelial cells and phagocytes, is also introduced. The platform can be used in lead 
compound profiling studies against C. pneumoniae infection. Mitogen-activated protein 
kinase (MAPK) inhibitors were found to inhibit the transfer of the infection, serving as 
reference compounds in future profiling studies.  
This work provides new information about the C. pneumoniae infection in monocyte-
macrophage cell models, while also offering valuable insight on the antichlamydial lead 
compounds, dibenzocyclooctadiene lignans. These lignans were shown to suppress the 
C. pneumoniae induced pathological changes in the host cells. With newly identified 
antichlamydial activities and novel study methods we can explore more impactful 
approaches to overcoming C. pneumoniae-induced chronic inflammatory diseases.  
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The obligate intracellular bacterium, Chlamydia pneumoniae is extremely widely spread 
in the world [1]. It is a respiratory tract pathogen that is usually treated with antibiotics 
[2], but its ability to disseminate throughout the body [3] and persist in the organs for a 
long period of time makes it particularly hard to eradicate. Intracellular persistence, 
together with the associated inflammatory host responses, have led to the hypothesis of 
C. pneumoniae being a risk factor for numerous severe chronic inflammatory diseases, 
such as atherosclerosis [4] and Alzheimer’s disease (AD) [5]. The current treatment 
methods are only effective against actively replicating bacteria, and persistent infections 
may therefore remain in the body. The diagnostics of C. pneumoniae infections in the 
clinic are efficient [6], but the serological markers of the pathogen often appear in a 
delayed manner. This can in many cases lead to wrong treatment decisions and, further, 
to the increased recalcitrance of the C. pneumoniae infection as a result of an 
inappropriately administered antimicrobial treatment [7].  
C. pneumoniae is able to disseminate within the body in peripheral blood mononuclear 
cells (PBMCs) and cause several effects inside these cells [3]. Infection in PBMCs 
induces proinflammatory changes in the cells e.g. inflammatory cytokine production, 
oxidative stress and lipid accumulation, which promotes the progression of chronic 
inflammatory diseases, such as atherosclerosis. It would therefore be of great importance 
to alleviate these infectious actions and eradicate the bacteria from the innate immune 
system cells [8]. In this thesis, the antichlamydial lead compound profiling is conducted 
with dibenzocyclooctadiene lignans, isolated from Schisandra chinensis, a plant 
frequently used in traditional Chinese medicine [9].  
The inhibition of the transfer of this pathogen from lung epithelium to other cells could 
also be an effective means to reduce the chronic inflammatory disease progression. We 
therefore developed a new method for studying the transfer of C. pneumoniae from lung 
epithelial cells to phagocytes. This method could be used in compound profiling, for 
finding new potential drug candidates against C. pneumoniae.   
16 
 
2. Review of the literature 
 
2.1 Chlamydia pneumoniae 
 
Chlamydia pneumoniae, a gram-negative bacterium, is a human pathogen whose 
primary site of infection is the respiratory tract [7, 10]. C. pneumoniae is an obligate 
intracellular bacterium and thus always needs a host cell for its replication and survival. 
C. pneumoniae is a widely spread bacterium and it is estimated that nearly everybody 
gets infected during their lifetime [1, 11]. A major proportion of the infections remain 
asymptomatic, but C. pneumoniae is able to cause several diseases, such as bronchitis, 
sinusitis and pneumonia. It is estimated that 10% of all pneumonia cases occurring 
outside hospitals are caused by C. pneumoniae. In addition to respiratory tract infections 
C. pneumoniae has been related to several other diseases, such as atherosclerosis [12, 
13], Alzheimer’s disease [5, 14] and asthma [15, 16]. To be involved in the progression 
of chronic inflammatory diseases occurring outside respiratory tract, C. pneumoniae 
must be able to migrate from the respiratory tract to other body sites. This migration 
occurs via PBMCs, mainly monocytes and macrophages [17, 18].  
In addition to actively replicating in the host cells, bacteria may be able to adopt a non-
replicative, dormant form that facilitates their prolonged persistence within the cells [7]. 
C. pneumoniae in PBMCs are typically spontaneously switching into such persistent 
state [8, 19]. Actively replicating bacteria are susceptible to macrolides, tetracyclines 
and quinolones [2, 20], and azithromycin is the golden standard antibiotic used for C. 
pneumoniae infections [21]. On the contrary, persistent bacteria are refractory to 
antibiotics and cannot be eradicated effectively [17]. In addition to their increased 
antimicrobial tolerance, persistent bacteria withstand host defenses for a long period of 




2.1.1 History and taxonomy 
 
Chlamydia pneumoniae has been identified as its own species within the Chlamydia 
genus quite recently, in 1989 [22]. Before it was even recognized as a Chlamydia, it was 
thought to be a virus causing atypical pneumonia [23]. C. pneumoniae, previously called 
TWAR (named after two previously identified isolates, TW-183 and AR-39), were 
initially isolated by Wang and Greyston from the eye of a child in Taiwan in 1965 [24]. 
In the beginning it was thought to be a Chlamydia trachomatis strain, yet it remained as 
an unidentified immunotype in 1968 and 1969 when the micro-immunofluorescence 
(MIF) serologic test for Chlamydia was developed. Later, when cell culture methods for 
Chlamydia were developed, TWAR was thought to be a new strain of Chlamydia psittaci 
[25], due to their inclusions sharing similarities and being iodine negative unlike those 
of C. trachomatis. After the MIF test was developed for TWAR antigens, it was realized 
that this new pathogen was frequently occurring, usually in respiratory infections, and at 
the end of the 1980s TWAR was recognized as a respiratory pathogen. Unique pear-
shaped inclusions and only a 10% DNA homology with C. trachomatis and C. psittaci 
[22] led to the identification of TWAR organisms as a new Chlamydia species 
Chlamydia pneumoniae, in 1989. 
C. pneumoniae species belongs to the phylum of Chlamydiae, and class of Chlamydia, 
order of Chlamydiales and family of Chlamydiaceae, which is divided into two genera: 
Chlamydia and Chlamydiphila. Chlamydia includes three species: C. trachomatis, C. 
suis, C. muridarum and Chlamydophila includes six species: C. abortus, C psittaci, C. 
felis, C caviae, C. pecorum and C. pneumoniae. Only C. trachomatis, C. psittaci and C. 
pneumoniae have been reported to infect humans. 
There has been a debate about the nomenclature of the genera and species of Chlamydia. 
In 1999, Everett et al [26], conducted new phylogenetic analyses of the 16S and 23S 
rRNA genes of Chlamydiales. The current taxonomy of the Chlamydiaceae family was 
proposed in which the genera and nomenclature of Chlamydia pneumoniae chanced to 
Chlamydophila pneumoniae. As not all scientists have accepted the division of the 
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species into the genera Chlamydia and Chlamydophila [27], the naming of C. 
pneumoniae is still controversial and both Chlamydia pneumoniae and Chlamydophila 
pneumoniae are used. In this work, only the name Chlamydia pneumoniae is used. 
 
2.1.2 Epidemiology and diagnostics 
 
Seroprevalence of C. pneumoniae increases with age and it is fairly uncommon with 
children under the age of 5 [10]. At all ages, C. pneumoniae infections are more common 
in males than in females. Seroprevalence reaches 50% by the age of 20 and by the age 
of 65 the seroprevalence is more than 70% [11]. C. pneumoniae is considered as the most 
common non-viral intracellular human respiratory pathogen. It is estimated to cause 
about 10% of community-acquired pneumonia (CAP) and 5% bronchitis and sinusitis 
cases [10], and the bacterium is frequently found in immunocompromised hosts. 
According to serological studies, C. pneumoniae infection is more frequently occurring 
than infections with the most studied species of Chlamydia, C. trachomatis [28], but for 
example in the Finnish register of infectious diseases there are a lot more C. trachomatis 
cases reported. In 2018, there were 293 reported C. pneumoniae cases and 14 839 C. 
trachomatis cases in Finland [29] which means that most C. pneumoniae infections are 
not diagnosed due to their minor or nonexistent symptoms.  
Current diagnostic standards include the serological measurement of C. pneumoniae 
antibodies from the blood using an enzyme immunoassay (EIA) [6]. The serological 
response to C. pneumoniae infection differs according to whether the infection is primary 
or a reinfection. In less than 6 months-old primary infections, both IgM and IgG antibody 
titers rise, often accompanied with the increase in IgA antibodies. In the case of 
reinfections, no IgM rise is seen, but IgG and sometimes IgA levels are elevated. It takes 
at least two weeks for the antibody titers to begin rising after the onset of symptoms and 
in children the process is even more prolonged. Together with the three to five days 
required for the completion of the laboratory tests, this delay markedly complicates the 





C. pneumoniae is classified as a gram-negative bacterium. The cell wall of Chlamydia 
contains two membranes, the outer and inner membrane that are separated from each 
other by a narrow periplasmic space [1] which has been shown to contain a 
peptidoglycan layer [30]. There are many cysteine-rich proteins in the chlamydial cell 
wall that can form disulfide cross-links with each other, which enhances the structural 
rigidity and osmotic stability of the extracellular bacteria [31, 32]. When bacteria 
internalize into the host cell, the disulfide bonds are reduced making the intracellular 
form of Chlamydia more fragile [33].  
Chlamydia switches between two structurally different forms, elementary bodies (EBs) 
and reticulate bodies (RBs). EBs are smaller of the two, approximately 0.3 µm in 
diameter. They are round, spore-like forms with nucleoids highly condensed by bacterial 
histone-like proteins HctA and HctB [34]. Still, EBs are reported to have a level of 
metabolism when being outside the cells [20]. RBs are bigger, around 0.8–1 µm in 
diameter. The nucleoids of RBs are loose and can thus be used for transcription [34, 35]. 
The outer membrane proteins of Chlamydia have been extensively studied. The three 
most abundant proteins, OmpA, OmcA and OmcB, form the chlamydial outer membrane 
complex (COMP) [36]. The membrane porin OmpA covers about 60% of all outer 
membrane protein content and is therefore also known as the major outer membrane 
protein (MOMP). The oxidation state of the disulfide bridges between the cysteine-rich 
OmpA proteins takes part in controlling the permeability of the membrane [37]. The 
proteins OmcA and OmcB form disulfide cross-links with each other, which in turn 
contributes to the rigidness of the bacteria [36].  
The outer membrane of C. pneumoniae also includes polymorphic membrane proteins 
(Pmps). There are 21 genes encoding Pmps, which cover 5% of the C. pneumoniae 
genome [38]. These genes are unique for the Chlamydiaceae family, and they have 
several roles in the chlamydial infection process. Pmps act as adhesins by facilitating the 
attachment of C. pneumoniae to host cells. These proteins have various binding 
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capabilities depending on the cell type [39]. In addition, Pmps may act as invasins. It is 
for example reported that Pmp21 binds the EGFR of epithelial cells and initiates the 
internalization of the bacteria [40]. Targeting the Pmp21 with a specific antibody has 
been shown to inhibit C. pneumoniae infection [41]. Pmp proteins appear to work 
together with other membrane proteins. For example, Pmp10 expression is reported to 
protect OmpA from cleavage by proteolytic enzymes [42]. These functions make Pmps 
important virulence factors in Chlamydia and they may provide putative targets for 
antichlamydial treatment. 
Another protein found in the membrane of C. pneumoniae is Heat Shock Protein 60 
(Hsp60), encoded by the gene groEL1. Heat shock proteins are widely expressed within 
eukaryotic and prokaryotic cells [43]. Hsp60 is synthesized when cells are under stress 
to act as a chaperone by preventing stress-induced protein misfolding. In addition, it is 
known to stimulate innate immune system cells, such as macrophages [44]. Hsp60 
protein can be recognized by host cells, which makes it a pathogen-associated molecular 
pattern (PAMP). 
 
2.1.4 Developmental cycle 
 
The chlamydial replication cycle occurs inside a membrane-bound structure called an 
inclusion [34]. It is formed when the Chlamydia becomes surrounded within a host 
plasma membrane-derived vacuole upon internalization [45]. The inclusion protects the 
bacteria from the host cell immune system and its fusion with the lysosomes is prevented. 
Bacteria multiply within the inclusion, whose size increases remarkably as the result. 
Newly synthetized lipids from the Golgi apparatus are transferred to and incorporated 
into the inclusion to make its growth possible [45, 46]. On the other hand, only few 
eukaryotic proteins are reported to be found in the inclusion membrane, and most of the 
proteins are of bacterial origin [47]. These proteins share a large hydrophobic region and 
are called the Inc family of proteins. IncA, IncB and IncC are the most abundant proteins 
in the inclusion membrane, but their functions have not been fully defined [48]. 
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C. pneumoniae has a unique biphasic lifecycle. It contains two morphologically distinct 
forms: infectious, extracellular EBs and metabolically active, intracellular RBs [34]. 
When C. pneumoniae infection is in the acute replicative state, EBs and RBs are mostly 
present inside the cells. The EBs occur only in the extracellular space between the 
replication cycles (Figure 1). 
 
 
Figure 1. The developmental cycle of C. pneumoniae. Elementary bodies (EBs) attach 
and enter into host cells. After internalization, EBs differentiate into reticulate bodies 
(RBs) that start to multiply. RBs then re-differentiate into EBs and become released from 
the cells. RBs can also convert into persistent forms, aberrant bodies (ABs), which are 
viable but non-replicating forms of the bacterium. 
 
2.1.4.1 Entry 
Chlamydial infection starts with the attachment of EB to the host cell. An interaction of 
C. pneumoniae with the host cell occurs in two stages. First, the bacterium attaches 
reversibly to the host cell, after which an irreversible attachment to a specific receptor 
occurs. The initial attachment of bacterial adhesins to host cells occurs through heparin 
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sulfate proteoglycans [49]. This attachment is reversible and happens through 
electrostatic interactions. Several proteins of the C. pneumoniae surface are reported to 
act as adhesins; OmpA, OmcB, Hsp70 as well as Pmps [49]. After this initial low-affinity 
binding, host cell receptors bind LPS or the outer membrane proteins of C. pneumoniae. 
Various receptors of human cells can bind C. pneumoniae (Table 1). Mannose 6-
phosphate receptor [50], epidermal growth factor receptor (EGFR) [40] and 
apolipoprotein E4 [51], for example, have been suggested to bind C. pneumoniae and 
initiate the internalization. The receptor type and its ligands can vary between the host 
cell type and the chlamydial strain, respectively [45]. In endothelial cells, insulin-like 
growth factor 2 receptor and mannose 6-phosphate receptor bind the bacterium [50], 
while the bacteria utilize the EGFR in epithelial cells for their internalization [40]. It 
remains unknown which receptors are responsible for the internalization e.g. into 
immune cells. 
 
Table 1. Proposed receptors of the host cells and ligands of C. pneumoniae involved in 
the internalization of bacteria. 













cells, U-87 MG 
Apolipoprotein E4 Unknown [51] 
Human epithelial 
cells, HEp2 
Unknown Pmp6, Pmp20 [38] 
MOMP, major outer membrane protein; Pmp, Polymorphic membrane protein. 
 
Immediately after receptor binding, chlamydial type three secretion system (TTSS) 
proteins are injected into the host cell to make the environment more suitable for the 
bacteria [52]. The TTSS consists of approximately 25 proteins [53], including 
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chaperones and ATPases, which are highly conserved across the organisms possessing 
this injection machinery [54, 55]. The Inc proteins of chlamydial inclusions are examples 
of TTSS effectors [48]. Another protein secreted by the TTSS is the translocated actin 
recruiting phosphoprotein family (Tarp) [56]. The chlamydial internalization into the 
host cells requires actin cytoskeleton remodeling at the site of internalization. Tarp is a 
protein that recruits actin at the entry site by directly interacting with it and promoting 
its nucleation, which is an initial and rate-limiting step in actin polymerization [57]. 
Studies also report the possible participation of vinculin, a cytoskeletal protein, which is 
involved in anchoring actin to a cell membrane [58].  Tarp colocalizes with vinculin and 
recruits it within the polymerized actin. In addition to actin remodeling, massive 
membrane remodeling occurs during the internalization of Chlamydia [59]. 
 
2.1.4.2 Differentiation and multiplication 
After internalization, the bacterial proteins are organized on the inclusion membrane, 
which enables the inclusion to evade the endosomal pathway and lysosomal fusion [59]. 
The inclusion then migrates near to the peri Golgi region, which is a nutrient rich region 
and thus advantageous to the bacteria [34, 45]. Within the inclusion, EBs quickly begin 
to differentiate into RBs [1]. The very dense, condensed DNA is loosened into a more 
fibrillar form and becomes transcriptionally active almost immediately after 
internalization. Proteins involved in nutrient acquisition, inclusion modification and 
transcription regulation are synthetized and more ribosomes are formed to enable 
effective protein synthesis [55]. The cell wall of the bacteria becomes more flexible and 
thinner, which makes it more fragile. RBs multiply by binary fission, in which DNA 
replicates and the cell is divided into two equally-sized daughter cells [60]. During the 
multiplication of RBs the inclusion expands, and at the end of the replication cycle it 
covers a large region of the host cell’s cytoplasm. Chlamydial proteases, such as 
chlamydial proteasome-like activity factor (CPAF) and high temperature requirement A 
(HtrA), are virulence factors that break up host cell proteins and cause several effects on 
the infected host cells [61]. They have an essential role in the chlamydial replication 
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cycle progression during this replication phase. RBs differentiate back to EBs 
asynchronously. During this secondary differentiation, proteins of the outer membrane 
protein complex (OmpA, OmcA, OmcB), are cross-linked in the outer membrane and 
the chromosome condensation genes (histone-like genes) become expressed [55]. At 48 
to 72 h post infection, newly formed EBs are released from the host cells. 
 
2.1.4.3 Exit 
At the end of the chlamydial replication cycle, approximately 48–72 hours after the 
infection, new EBs are released from the host cell by two distinct mechanisms: by host 
cell lysis or by the extrusion pathway [62]. In the lysis exit, the inclusion membrane first 
dissociates, followed by the breakdown of the host plasma membrane, and free EBs 
become released to the extracellular space [62]. In extrusion, the whole inclusion pinches 
out from the cell leaving the host cell intact. In this case, EBs are left inside the 
membrane-bound vacuole in the extracellular space. An inclusion can also be released 
from the cell only partly leaving some of the bacteria inside the host. The extrusion 
vacuole is suggested to protect EBs in the extracellular space from phagolysosomal 
killing [63], and EBs in extrusions have been shown to survive better in cell culture 
compared to free EBs. The extrusion vacuoles can also be internalized as such into 
phagocytes in which they can disseminate the infection, so exit by extrusion seems to be 
beneficial for chlamydial survival also in this regard. It remains unknown whether C. 
pneumoniae can be released from the cells via both exit approaches. As opposed to other 
Chlamydia species, there is no experimental data available of the capability of C. 
pneumoniae to exit by host cell lysis. Instead, extrusion has been demonstrated also in 




2.1.5 Persistent infections 
 
If, during the active development, Chlamydia experiences stressful conditions, such as 
nutrient deprivation or antibiotic treatment, its replication cycle may be interrupted [7]. 
This prompts Chlamydia to enter an inactive state in which they can withstand such 
conditions for prolonged times. Also known as persistence, this chlamydial stress 
response is transient, and the replication cycle can revert into the normal state upon the 
re-establishment of favorable conditions. 
The morphologically distinct persistent bacteria are called aberrant bodies (ABs) or 
aberrant RBs [34]. ABs can be identified by electron microscopy based on their enlarged 
size and irregular shape. Chlamydial persistence can be induced by various stimuli in 
vitro. Exposure to the penicillin group of antibiotics [65], nutrient deprivation (e.g. iron, 
amino acids, glucose) [66], interferon-γ (IFN-γ) exposure [67], tobacco smoke [68] 
among other stress inducers have been reported to initiate persistence. Penicillin blocks 
the RB multiplication and redifferentiation into EBs [7]. IFN-γ is a cytokine that induces 
the immune system to fight the pathogens and it also increases the catabolism of 
tryptophan [69], which is an essential amino acid for Chlamydia.  
When Chlamydia evades the innate immune responses of the cells and enters persistence, 
RB-to-EB conversion is blocked and cell division stops. Gene expression is also altered. 
The genes involved in RB-to-EB differentiation, such as omcB and hctB, are not 
expressed and stress response genes, such as heat shock proteins grpE, groES and htrA, 
are overexpressed instead to protect the bacteria in stressful conditions [70].  
In addition to in vitro persistence models, Chlamydia can also enter the persistent state 
in vivo. With immunostaining, aberrant bodies from different Chlamydia species have 
been observed in various tissues and chlamydial DNA has been found in tissues long 
after the obvious infection [7]. In several cases the bacteria are in a non-cultivable state 
when isolated, which indicates a persistent infection. A key outcome of C. pneumoniae 
persistence is reoccurring infections. It is hypothesized that during Chlamydia infection, 
a subpopulation of bacteria enters into a persistent state due to stressful conditions, while 
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others continue to replicate normally. Replicating bacteria can eventually be eradicated 
by the host immune system or by antibiotic treatment, while persistent bacteria remain 
and continue to manipulate their microenvironment to their favor, generating a chronic 
and long-term infection with minimal symptoms. According to murine models, it seems 
that immune reactions can induce C. pneumoniae persistence, and when the stressful 
conditions have subsided, the bacteria can be reactivated in the tissues [71]. This 
provides further evidence to the notion that persistence is the main driver behind 
reoccurring C. pneumoniae infection. A similar phenomenon has been identified also in 
other intracellular bacteria. For example, Staphylococcus aureus and Escherichia coli 
have been reported to enter the persistent state inside host cells under stressful conditions 
[72, 73]. 
 
2.2 Chlamydia pneumoniae in innate immune system cells 
 
The primary site of infection of C. pneumoniae is the respiratory tract and in there, the 
epithelial cells [74]. In addition, C. pneumoniae can infect various other cell types, 
among which the most studied are the innate immune system cells, including peripheral 
blood mononuclear cells: monocytes and macrophages [8, 75, 76]. C. pneumoniae has 
been shown to change the normal functions of these cells in several ways. These changes 
are associated with chronic inflammatory diseases, especially the progression of 
atherosclerosis [77]. For example, the bacterium induces inflammatory cytokine 
production, alters the redox balance and induces foam cell formation of macrophages, 
which are particularly important in atherosclerosis development [8]. 
 
2.2.1 Dissemination in the body 
 
C. pneumoniae has been found in various tissues throughout the body. The transport of 
C. pneumoniae from the respiratory tract to other body sites occurs via PBMCs, 
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including mainly monocytes that can differentiate into macrophages when entering their 
target tissue [3]. The dissemination has been studied with murine models [18, 78]. When 
mice were inoculated intranasally or intraperitoneally, the bacteria could be found in 
alveolar macrophages and peritoneal macrophages, respectively, and also in monocytes. 
When infected macrophages were injected into uninfected mice, the bacteria were found 
in lungs, lymph nodes, the thymus and spleen. Rabbit models have also been used in 
dissemination studies [3]. Rabbits were infected intratracheally and after the inoculation 
bacteria could be detected from granulocytes, alveolar epithelium and alveolar 
macrophages. The alveolar macrophages transferred the bacteria into lymph nodes and 
from there C. pneumoniae was disseminated within PBMCs into the spleen and aorta.  
C. pneumoniae DNA has been found in PBMCs of patients with cardiovascular disease 
[79] and viable bacteria have also been extracted from atherosclerotic arteries [80, 81]. 
One mechanism that C. pneumoniae employs to transfer into macrophages is silent entry 
through polymorphonuclear leucocytes (PMN) [82]. When C. pneumoniae infects the 
respiratory tract, PMNs are recruited to the infection site and the bacteria may infect 
them. Infected PMNs recruit monocytes to the infection site and, when the infection 
leads to the apoptosis of PMNs, the monocytes phagocytize them. This mechanism is 
suggested to support C. pneumoniae internalization into monocytes. 
 
2.2.2 Infection in monocytes and macrophages 
 
2.2.2.1 Inflammatory cytokine production 
Cytokines are small proteins secreted by various types of cells, including immune system 
cells [83]. They act as signal molecules and immunomodulatory agents. C. pneumoniae 
infection induces both, pro- and anti-inflammatory cytokine production, in immune 
system cells. For example, infection has been shown to induce the production of tumor 
necrosis factor α (TNF-α), IL-1β and IL-6 in several cell lines. C. pneumoniae-induced 
cytokine production in different cell lines is reviewed in Table 2. 
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Table 2. The cytokines induced by C. pneumoniae in different cell types of innate 
immune system cells. 
Cell line Organism cytokine Reference 
Mono Mac 6 human TNF-α, IL-1β, IL-6 [84] 
DCs mouse TNF-α, IL-12p40 [44, 85] 
RAW264.7 mouse TNF-α, IL-1β, IL-6, MCP-1 [86] 
HPBMCs human TNF-α, IL-1β, IL-6, IFN-α, IL-8, IL-
10, MCP-1 
[87-89] 
AM human TNF-α, IL-1β, IL-8 [90] 
THP-1 human TNF-α, IL-1β, IL-8, IL-12, IL-10 [91-93] 
AM, alveolar macrophages; HPBMC, Human peripheral blood mononuclear cells; DC, 
dendritic cells; IFN-α, interferon α; IL, interleukin; MCP, Monocyte chemoattractant 
protein-1; TNF-α, tumor necrosis factor α. 
 
2.2.2.2 Redox balance alteration 
In addition to cytokines, innate immune system cells produce also other types of 
regulators in response bacterial infection. These include reactive oxygen species (ROS), 
such as hydrogen peroxide (H2O2) and superoxide (O2-), and reactive nitrogen species 
(RNS), such as nitric oxide (NO) [94]. ROS are produced in endothelial cells and 
macrophages through NADPH oxidase (NOX), as well as through the mitochondrial 
respiratory electron transport chain. An excessive amount of ROS in the cells induces 
oxidative stress which promotes the progression of inflammatory diseases. C. 
pneumoniae has been reported to alter the redox balance of infected cells [95], e.g. by 
inducing the ROS and NO production [96, 97]. In murine macrophages, C. pneumoniae 
has been reported to induce both the NOX-induced and mitochondrial ROS production 
[98]. Although this ROS production is a defense mechanism against C. pneumoniae it 
has been reported that the pathogen is able to survive high ROS levels by concomitantly 
altering the antioxidant levels of the cells [99]. In addition, C. pneumoniae has been 
reported to induce NO production in murine macrophages [97]. NO is synthetized by 
inducible nitric oxide synthase (iNOS), and C. pneumoniae is suggested to induce NO 
production through altering iNOS expression [100, 101]. 
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While C. pneumoniae infection alters the redox state of the host cells, it is also reported 
that the alteration may in turn affect the C. pneumoniae infection phenotype in mouse 
macrophages [99, 102]. The suppression of oxidative stress by antioxidant 
supplementation increased the inclusion formation in the cells, and when the redox status 
was increased, the inclusion formation was correspondingly decreased. It is suggested 
that C. pneumoniae switches into a more persistent state in the intracellular oxidative 
environment, which leads to the reduced inclusion formation. 
Alleviating the oxidative stress caused by C. pneumoniae infection has been considered 
as a potential treatment option in the prevention of C. pneumoniae-induced 
atherosclerosis [95]. Diet-derived antioxidants, vitamin E, resveratrol and curcumin as 
well as COX2 inhibitors have been shown to prevent C. pneumoniae-induced ROS 
production in different cell lines. 
 
2.2.2.3 Glutathione metabolism 
Glutathione (γ-glutamyl-cysteinyl-glycine, GSH) is a major antioxidant in cells [103-
105]. It is a tripeptide that is present in all tissues throughout the body. It efficiently 
scavenges ROS and other free radicals, including hydroxyl radicals, lipid peroxyl 
radicals and H2O2. The scavenging can occur directly or through enzymatic reactions, in 
which GSH is oxidized into glutathione disulfide (GSSG). GSSG is then converted back 
to GSH by reductases in the presence of NADPH. GSH prevents the oxidation of 
biomolecules in the cells and it also reacts with several biological metabolites and 
xenobiotics, i.e. foreign chemical or biological substances. In addition to the scavenging 
activity, GSH also has a more general role in metabolism. Among other functions, it 
takes part in prostaglandin and leukotriene synthesis and transports and stores cysteine. 
In addition, GSH has several regulatory functions involved in intracellular redox status, 
gene expression, DNA and protein synthesis, signal transduction, the proliferation and 
apoptosis of the cells as well as mitochondrial function. 
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GSH is synthetized in the cytosol, after which it may be transferred into other cellular 
compartments [106]. A part of the GSH pool remains constantly in the cytosol, but the 
rest is distributed into the endoplasmic reticulum (ER), nucleus and mitochondria. GSH 
is also distributed between different organ systems, particularly liver, kidneys and 
pancreas, where GSH is needed to detoxify xenobiotics [107-109]. 
The cellular GSH balance is maintained between consumption and synthesis [106]. Due 
to their strong association with cellular oxidative stress, altered GSH levels have been 
associated with several pathologies, including cardiovascular [110] and neurogenerative 
diseases [111], cancer [112] and diabetes [113]. 
C. pneumoniae infection has been reported to alter cellular GSH levels [114]. For 
instance, it was demonstrated to suppress the GSH pools in human T cells and also in 
murine RAW264.7 macrophages [99]. On the other hand, GSH supplementation 
demonstrated to increase C. pneumoniae replication in RAW264.7 cells, which also links 
GSH metabolism to C. pneumoniae infection and survival [102]. This is also associated 
with the chlamydial infection phenotype and the induction of persistence, as described 
above.  
C. pneumoniae has also been reported to affect the antioxidative enzyme production in 
murine macrophages [99]. It induced the ROS-scavenging superoxide dismutase (SOD) 
and glutathione peroxidase (GPx) even after being heat-inactivated, which implies that 
bacterial replication is not necessary for the effect. Infection additionally induced the γ-
cysteine ligase (GCL) production, which catalyzes glutathione biosynthesis in the 
macrophages. These may be compensatory mechanisms arising from the C. pneumoniae-
induced ROS/NO production and the decreased levels of GSH. 
 
2.2.2.4 Foam cell formation 
Foam cell formation is one of the first hallmarks of atherosclerosis [115]. Foam cells are 
macrophages in which lipids are accumulated into vacuoles, giving the cells a foamy 
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appearance. Foam cells accumulate in arterial walls and initiate the formation of an 
atheroma [116]. Several factors promote foam cell formation, including inflammatory 
cytokines, transcription factors, a lipid-rich environment, and oxidative stress. In 
oxidative environment, LDL is oxidized and is thus more likely to accumulate in the 
cells [117]. 
Scavenger receptors are responsible for recognizing and internalizing the oxidized LDL 
into the cells [94]. There are ten different classes of scavenger receptors, SR-A to -J 
[118]. The ones most related to foam cell formation are SR-A and SR-B. There are 
several reports of the cluster of differentiation 36 protein (CD36), which belongs to SR-
B family, being involved in macrophage foam cell formation. It is suggested that 60–
70% of macrophage foam cell formation is CD36-dependent [119, 120]. CD36 is an 
integral membrane protein found in many cell types. Native, unmodified LDL 
internalizes into the cells by different mechanisms than oxidized LDL. One such 
mechanism is through fluid-phase pinocytosis, which is an endocytic pathway without 
any specific receptor binding [121, 122]. 
After LDL is internalized, lipoproteins are delivered to the late endosome where they are 
broken up to cholesterol and fatty acids [123]. The esterification of the free cholesterol 
is another phenomenon that takes place in the macrophage foam cells [124]. Cholesteryl 
esters are more likely to accumulate into lipid vacuoles and promote foam cell formation 
[125]. The free cholesterol inside the cells is esterified by acyl-coenzyme A cholesterol 
acyltranferase 1 (ACAT1) [124]. Cholesteryl esters are simultaneously hydrolyzed back 
to free cholesterol by lysosomal acid lipase (LAL) and the rate of cholesterol 
accumulation into lipid droplets is determined by the balance of esterification and 
hydrolysis.  
Another important factor concerning lipid accumulation and foam cell formation is lipid 
efflux from the cells. Lipid accumulation itself induces efflux, which occurs mostly via 
the ATP-binding cassette (ABC) transporters ABCA1 and ABCG1 [126]. ABCA1 
transports cholesterol from macrophages to apolipoprotein A1 (ApoA1). ApoA1 is a 
32 
 
major component of HDL particles that transfer lipids out of the cells. The ABCA1 on 
the macrophage surface forms a complex with ApoA1, connecting the HDL particle to 
the cell, and then transports cholesterol from the cell to the HDL. A summary of lipid 
transportation in cells is presented in Figure 2. 
   
 
Figure 2. Cholesterol traffic inside the macrophage foam cells. Oxidized LDL is taken 
into the cells by scavenger receptors i.e. CD36 and SR-A. Unmodified LDL, in turn, is 
taken into the cells by pinocytosis. LAL breaks LDL into fatty acids and pure cholesterol 
(C), which can be esterified by ACAT1. Oxidized LDL, cholesteryl esters (CE) and other 
lipids accumulate into lipid droplets, which are formed inside the foam cells. Lipids are 
transported out of the cells via the efflux protein ABCA1. 
 
Peroxisome proliferator-activated receptor gamma (PPARγ) activity plays an important 
role in several events related to lipid accumulation and foam cell formation. PPARγ is a 
nuclear receptor that regulates the expression of the genes involved in lipid and glucose 
metabolism [127], such as CD36 [128] and ACAT1 [129]. PPARγ also takes part in 




C. pneumoniae has been associated with macrophage foam cell formation and atheroma 
development in human and murine cell lines [131-134]. The Hsp60 of C. pneumoniae is 
reported to increase LDL oxidation [135, 136]. Infection has been also shown to increase 
the amount of cholesterol esters in human macrophages [131] as well as in murine 
macrophages, in which foam cell formation was shown to be induced by chlamydial LPS 
[137]. The increase in cholesterol was revealed to occur via ACAT1 activation in THP-
1 macrophages [138]. It has also been reported that C. pneumoniae reduced the ABCA1-
related cholesterol efflux [139] and PPARγ activity [140] in THP-1 macrophages. 
 
2.2.2.5 Cell signaling pathways 
C. pneumoniae is recognized by immune cells though pattern recognition receptors 
(PPRs), toll like receptors (TLRs), and nucleotide-binding oligomerization domain-like 
receptors (NLRs). TLRs localize in the cell membrane and recognize extracellular C. 
pneumoniae. NLRs are intracellular receptors and recognize the bacteria inside the cells. 
Several studies attempted to identify the TLRs responsible for this recognition, and both 
TLR2 and TLR4 have been proposed [141]. TLR activation leads to several responses 
in the cells via the transcription factors NF-κB, which regulates the expression of genes 
involved in survival, immune responses and inflammation [142]; and PPARγ, which 
plays an important role in lipid metabolism in the cells [134]. 
TLR activation leads to the induction of myeloid differentiation primary response 88 
protein (MyD88), an adaptor that relays the outside signals through TLR to the 
intracellular signaling system by linking them with the IL-1R-assosiated kinase (IRAK) 
[143]. Another adaptor protein activated by TLRs, the TNF receptor-associated factor 6 
(TRAF6), then activates the MAPK kinase pathways c-Jun NH2-terminal kinase (JNK) 
pathway and p38 mitogen-activated protein kinase pathway [144], resulting in the 
regulation of PPARγ. TRAF6 binds a complex including transforming growth factor-β-
activated kinase (TAK1), which in turn activates I-kappa B kinase (IKK) complex, 
finally leading to the activation of nuclear factor-kappa B (NF-κB) [145]. Intracellular 
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NLRs activate receptor-interacting-serine/threonine-protein kinase 2 (RIP2) which also 
induces MAPK signaling and NF-κB activation [146]. 
C. pneumoniae has been reported to activate the MAPK signaling pathway. Chlamydial 
antigens were discovered to activate the JNK pathway in murine [147] and human [134] 
macrophages. Furthermore, C. pneumoniae infection has been reported to affect NF-κB 
[139, 148] and PPARγ [149] pathways. A non-exhaustive presentation of the signaling 
pathways induced by C. pneumoniae are presented in Figure 3. 
 
Figure 3. C. pneumoniae-induced cell signaling pathways related to inflammation and 
lipid metabolism. C. pneumoniae (Cpn) is recognized by TLRs and NLRs in immune 
cells and it causes immune reactions by activating the NF-κB transcription factor. The 








2.2.3 Links to chronic inflammatory diseases 
 
2.2.3.1 Atherosclerosis 
The association of C. pneumoniae with atherosclerosis dates back for decades. C. 
pneumoniae was first discovered in an atherosclerotic plaque by Shor et al in 1992, who 
used transmission electron microscopy, immunohistochemistry, and PCR [150]. This 
was followed by several other discoveries of C. pneumoniae, including viable bacteria, 
in atherosclerotic lesions [12, 80, 151, 152]. The cultivation of C. pneumoniae after 
extracting it from atheromatous tissues has been difficult, the most likely reason being 
that bacteria are in their non-replicative persistent state.  
Several seroepidemiological studies have been carried out to characterize the association 
between atherosclerosis and C. pneumoniae. The first study was conducted by Saikku et 
al. in 1988 [153] followed by several others [13, 154-157], most of them finding a 
significant serological association between the disease and C. pneumoniae infection.  
Murine and rabbit models have provided more evidence of the association between C. 
pneumoniae and atherosclerosis development, since C. pneumoniae infection increased 
the atheroma formation in both models, and viable bacteria could be isolated from the 
lesions afterwards [158, 159]. 
The mechanisms by which C. pneumoniae promotes atherosclerosis progression have 
been studied widely, and there is evidence that C. pneumoniae might have a role in all 
stages of the disease [13]. Inflammation within the arterial wall is considered to be the 
initial event in atherosclerosis progression and C. pneumoniae may take part in that by 
infecting the vascular endothelial cells, which leads to inflammatory cytokine production 
as well as the migration and adhesion of leucocytes [160]. In addition to foam cell 
formation, C. pneumoniae may contribute to the latter stages of atheroma development. 
Infected endothelial cells secrete growth factors which, together with cytokines from 
macrophages and oxidized LDL, can promote smooth muscle cell proliferation and 
migration [161]. The smooth muscle cells in turn secrete molecules that promote the 
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atheroma formation. Matrix metalloproteases (MMPs) are known to weaken the 
atherosclerosis plaques and promote their rupture [162]. Chlamydial Hsp60 stimulates 
MMP production in atheroma and can thus be additionally involved in atheroma rupture 
[163]. 
 
2.2.3.2 Alzheimer’s disease 
Because of a previously-established connection between microorganisms and neurologic 
disorders, researchers have investigated the association of C. pneumoniae with 
Alzheimer’s disease (AD) for a long time. Balin et al, in 1998, demonstrated with 
immunological labeling and PCR that C. pneumoniae antigens and DNA were present 
in the areas in the brain showing neuropathology in AD patients [164]. Several 
subsequent trials attempted to repeat these results and provide further evidence for the 
relationship between the pathogen and AD, but these attempts were unsuccessful [165-
167]. Later on, several studies have discovered C. pneumoniae in the brain tissue of AD 
patients, thus strengthening the link between C. pneumoniae and AD [168-170]. Similar 
associations have also been demonstrated in animal models [14]. One suggested 
mechanism by which C. pneumoniae affects the brain is connected to the ApoE-ɛ4 allele. 
ApoE is a major apolipoprotein in the brain, and its variant, produced from the allele ɛ4, 
is associated with a higher risk of Alzheimer’s disease [171]. Patients with the ɛ4 allele 
have also shown to contain increased amount of C. pneumoniae infected cells. This 
isoform of ApoE4 also seems to enhance the attachment of C. pneumoniae to the cells 
[172]. 
 
2.2.3.3 Obstructive lung disease 
C. pneumoniae has been related to both the development and severity of asthma [173, 
174]. It can infect alveolar macrophages and lung monocytes, which causes 
inflammatory cytokine production that is common in allergic and asthma patients [175]. 
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Such infection also causes immunopathologic damage to lung tissue. C. pneumoniae-
specific antibodies have also been found in a majority of patients with severe asthma, 
compared to the samples from healthy donors [174]. Azithromycin, the standard 
antibiotic used in C. pneumoniae infections, has been found to alleviate asthmatic 
symptoms and improve the quality of life of the patients, which further points towards 
the role of infectious processes in chronic respiratory illnesses [176]. However, 
azithromycin itself has immunomodulatory effects, which could have contributed to the 
positive outcomes. 
There is also evidence that C. pneumoniae infection is associated with chronic 
obstructive pulmonary disease (COPD). Bacteria have been found in bronchioli, alveoli 
and alveolar macrophages extracted from COPD patients [177]. 
 
2.3 Antichlamydial drug discovery and lead compound profiling 
 
2.3.2 Current treatment 
 
Antibiotics that interfere with DNA and protein synthesis are used for chlamydial 
infections. Tetracyclines (tetracycline, doxycycline), macrolides (azithromycin) and 
quinolones are most commonly used [2]. 
Azithromycin and other macrolides are the most commonly used antibiotics for C. 
pneumoniae infections. Their mechanism of action is to bind the bacterial ribosome S50 
subunit and prevent peptidyl-tRNA binding to the P-site of the ribosome, which leads to 
the inhibition of protein synthesis in bacteria [178]. Tetracyclines also target microbial 
protein synthesis, but they do so by binding the 30S subunit of the ribosome, thus 
inhibiting the binding of aminoacyl-tRNA to the A-site of the ribosome. Quinolones 
interfere with the unwinding and replication of bacterial DNA. Regardless of the 
treatment standards for C. pneumoniae, the delays in diagnosis often lead to non-optimal 
antibiotic treatment, as is the case with all persistent bacteria [179]. In Finland, the 
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standard procedure is to start antibiotics immediately when pneumonia is diagnosed, or 
even before if symptoms are strongly indicating it [180]. Because the most common 
causative agent of community acquired pneumonia is Streptococcus pneumoniae, the 
standard antibiotic of choice is amoxicillin, a beta-lactam antibiotic [181]. It has been 
reported, however, that beta-lactam antibiotics, such as penicillin, ampicillin, 
amoxicillin and carbenicillin induce chlamydial persistence in vitro [7, 65, 182]. 
Therefore, not only can beta-lactam antibiotic treatment for pneumonia be ineffective 
due to the non-susceptible pathogen, but it may also promote the development of a 
persistent C. pneumoniae infection.  
 
2.3.3 Natural products as lead compounds 
 
Several approaches have been applied for the discovery of novel antichlamydial 
compounds. Existing drugs such as statins [183, 184] and heparins [185] have been 
studied for this purpose, but new investigational compounds have been proposed, 
including 2-arylbenzimidazoles [186] and β2,2-aminoacid derivatives [31]. An alternative 
approach has been to explore natural compounds. Natural products have been used as 
herbal medication since the ancient times, but the drug discovery of purified compounds 
from natural products has only been ongoing since the 19th century [187]. It is a 
challenging and time-consuming approach for drug discovery, because it includes the 
identification and phytochemical as well as pharmacological characterization of 
bioactive compounds [188]. Still, there have been many successful discoveries from 
natural products, common examples being acetylsalicylic acid, an anti-inflammatory 
drug originally derived from the willow plant (Salix alba) [189]; quinine, an antimalarial 
drug from the bark of the cinchona tree (Cinchona officialis) [190]; opioid pain killers 
from opium poppy (Papaver somniferum) [191]; digoxin, a cardiac medicine, from 
common foxglove (Digitalis purpurea) [192], and paclitaxel, an anticancer drug from 
the bark of the Pacific yew tree (Taxus brevifolia) [193].  
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According to estimates [188], there are 75 000 species of higher plants of witch only 
10% have been used in traditional medicine, and only 1 to 5% have been studied 
scientifically. Exploring the active compounds of products that have been used as 
traditional medicine has been proven a fruitful approach in drug discovery, providing 
many possibilities for finding new effective and safe lead compounds. 
During the past few decades, the efficacy of the available antimicrobials has been in 
steep decline due to the rapid emergence of antibiotic resistance in pathogens. This poses 
a serious threat for healthcare. According to the World Health Organization (WHO), we 
are heading towards ‘a postantibiotic era’, in which minor injuries and common bacterial 
infections can kill people, because there are no efficient antibiotics left [194]. Even 
though approximately two thirds of current antimicrobials are derived from the nature 
[195], pharmaceutical companies have very little research interest in naturally derived 
compounds. The most challenging tasks in natural product-based drug discovery are the 
target deconvolution, the active compound identification and the synthesis of the often 
very complicated structures. Several natural products, especially phenolic compounds, 
have been shown to have antichlamydial activity (Table 3). Therefore, the exploration 





Table 3. Examples of naturally occurring phenolic compounds with activity against C. 
pneumoniae. 
Compound group Example compounds Reference 
Flavones Luteolin  [196-198] 
Flavonols Quercetin, rhamnetin [196-199] 
Flavanones Naringin [196] 
Isoflavones Biochanin A, genistein, rotenone [196, 200, 201] 
Coumarins Coumarin [196, 202] 
Catechins Catechin, epigallocatechin gallate [196, 202] 
Phenolic acids Caffeic acid, rosmarinic acid [196, 197] 
Stilbenes Resveratrol [196] 
Lignans Schisandrin B, schisandrin C [203] 
 
 
2.3.4 Future prospective 
 
It is estimated that bringing new drug to the market takes 10 to 15 years and costs billions 
of dollars [204]. The methodology in antichlamydial drug discovery and lead profiling 
studies differs from that of several other pathogens. Since Chlamydia is an obligate 
intracellular bacterium and not viable outside cells, infecting mammalian cells is a 
crucial step in the experiments. This makes the drug discovery considerably more time-
consuming when compared to typical antimicrobial research workflows. Permissive cell 
lines are widely used in the drug development studies, and the detection of chlamydial 
replication is a standard method in Chlamydia-research [205, 206]. This approach leaves 
the non-replicative, persistent infections unnoticed. Considering that persistent 
infections occur spontaneously in several cell lines, including the ones used in the study 
of chronic inflammatory diseases, this limitation is critical. Thus, in addition to new 
potential antichlamydial drugs, new methods for antichlamydial lead profiling are also 
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needed to enhance the discovery of effective drugs against active and persistent C. 
pneumoniae infections. 
 
2.4 Lignans from Schisandra chinensis 
 
Schisandraceae is a family of flowering plants that belongs to the order of 
Austrobaileyales [207]. Schisandraceae are divided into three genera: Kadsura, Illicium 
and Schisandra. Apart from a few exceptions, all of the approximately 90 species of 
Schisandraceae are distributed in southeastern Asia, mainly in China, and they have 
been widely used in traditional Chinese medicine. Schisandra chinensis, more 
commonly known as the Chinese magnolia-vine, is one of the most used medicinal plants 
among Schisandraceae [9]. S. chinensis produces red berries that grow in hanging 
clusters, and these berries are the parts used for herbal remedies [208]. In addition to 
China, S. chinensis berry extract has also been used in the western countries. Its 
traditional applications have included the treatment of GI- and respiratory tract diseases, 
cardiovascular diseases, fatigue and insomnia [9]. 
Lignans are polyphenols, frequently occurring metabolites that are found in various 
plants. Their structure includes two or more phenylpropanoid units [209]. 
Dibenzocyclooctadiene lignans occur in several species of the genera Schisandra [210] 
and Kadsura [211]. In addition to two phenyl rings, dibenzocyclooctadiene lignans 
contain an eight-ring structure, which makes them unusual among polyphenols [209]. 
Dibenzocyclooctadiene lignans are dominant secondary metabolites in the S. chinensis 
berries and they have been found to have many biological activities [9, 208, 212]. 
Approximately 150 lignans with the dibenzocyclooctadiene structure have been 
discovered [213] and in most part in S. chinensis, which is the reason these molecules 
are often referred to as S. chinensis lignans [214]. The most abundant 
dibenzocyclooctadiene lignans in the berries are schisandrin, schisandrin B, schisanterin 
A and schisanterin B. 
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Schisandrin lignans have been widely studied, but the mechanisms of action of these 
compounds are only partially understood. They have been reported to have cardio- [215], 
neuro- [216] and hepatoprotective [217] effects and they have also demonstrated 
anticancer properties by preventing metastasis formation in the murine breast cancer 
models [218]. They act as immunomodulatory agents by reducing LPS-induced cytokine 
production [219, 220] as well as the production of ROS and RNS [221]. The 
antioxidative properties of schisandrin lignans have been shown to be linked to the 
glutathione homeostasis in various cell types [217, 220, 222], but there is a limited 
amount of data available on immune cells and none on monocytes and macrophages. 
Very few reports have explored the putative antimicrobial activity of schisandrin lignans 
or the berry extract, but previous studies conducted in our laboratory introduce the 
antichlamydial activity of single dibenzocyclooctadiene lignans [203]. 
There is a limited amount of data available about the absorption, distribution, 
metabolism and excretion properties of schisandrin lignans. A few bioavailability studies 
have been conducted in mice for schisandrin and schisandrin B, and it seems that oral 




3. Aims of the study 
 
The C. pneumoniae infection in monocytes and macrophages is a major problem since 
the infection changes the normal function of these cells and the pathogen switches into 
a persistent form. Susceptibility screenings of potential antichlamydial compounds are 
typically done in permissive cell lines, in which the persistent infection remains 
unnoticed. The aims of this thesis focused on establishing a workflow for the evaluation 
of potential antichlamydial compounds on their ability to suppress C. pneumoniae-
induced pathologies in monocytes and macrophages. The objectives also included the 
profiling of antichlamydial lead compounds, dibenzocyclooctadiene lignans, in C. 
pneumoniae-infected monocyte-macrophage cell models. 
 
The specific aims of the work were: 
 To study the impact of schisandrin lignans on the redox status of a human 
monocytic cell line and on the activation of human innate immune system cells 
(I) 
 To study the impact of schisandrin lignans on the redox status in macrophage 
cell lines and its effect on the C. pneumoniae replication status (II, IV) 
 To study the impact of schisandrin lignans on foam cell formation and its 
connection to gene expression related to lipid accumulation and glutathione 
metabolism (IV)  
 To examine the transfer of C. pneumoniae from epithelial cells to phagocytes 






4. Materials and methods 
 
4.1 Studied compounds 
 
The main compounds used in the studies are three dibenzocyclooctadiene lignans, 
originally isolated from the berries of Schisandra chinensis (Table 4). Schisandrin was 
purchased from Sigma-Aldrich (St. Louis, MO, USA) and schisandrin B and schisandrin 
C from Fine Tech Industries (London, UK). The compounds were dissolved in dimethyl 
sulfoxide (DMSO) yielding a concentration of 20 mM and they were stored at -20 °C. 
The lignans were used in experiments at the final concentrations of 25 µM and 50 µM.  
Three MAPK inhibitors, c-Jun N-terminal kinase (JNK) inhibitor (SP600125), p38 
mitogen activated protein kinase inhibitor (SB203580) and extracellular signal-regulated 
kinase (ERK) inhibitor (FR180204), were used in the studies. They were purchased from 
Tocris Bioscience (Bristol, UK) and dissolved in DMSO at a final concentration of 20 













Table 4. Compounds used in the studies. 








    
7432-28-2 
Schisandrin B 
    
61281-37-6 
Schisandrin C 








     
129-56-6 
SB203580 
   
152121-47-6 
FR180204 
     
865362-74-9 
 
MAPK, Mitogen-activated protein kinase 
 
4.2 Host cell lines 
 
Human epithelial cell line, HL, obtained from Professor Pekka Saikku (National Institute 
of Health and University of Oulu, Finland) was originally isolated from the human 
respiratory tract [225]. HL cells were grown in Roswell Park Memorial Institute medium 
1640 (RPMI 1640, (BioWhittaker/Lonza, Basel, Switzerland), supplemented with 7.5% 
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fetal bovine serum (FBS) (Lonza), 2 mM L-glutamine (Lonza) and 20 µg/ml gentamicin 
(Sigma-Aldrich).  
Human monocytic cell line, THP-1 (ATCC TIB-202), originally isolated from acute 
monocytic leukemia patient, was obtained from the American Type Culture Collection 
(ATCC, Manassas, VA, USA) and maintained in RPMI 1640 Dutch modified medium 
(Gibco/Invitrogen; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 
10% FBS (Lonza), 2 mM L-glutamine (Lonza), 20 µg/ml gentamicin (Sigma-Aldrich) 
and 0.05 mM of mercaptoethanol (Gibco, NY, USA). When appropriate, THP-1 cells 
were differentiated into macrophages by incubating them for 48–72 h with 160 nM 
phorbol-12-myristate-13-acetate (PMA, Sigma-Aldrich). 
Murine macrophage cell line, RAW264.7 (ATCC TIB-71), obtained from ATCC, 
originally isolated from an Abelson murine leukemia virus-induced tumor, were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco), supplemented 
with 10% FBS (Lonza) and 20 µg/ml gentamicin (Sigma-Aldrich). 
All cell lines were cultured at 37 °C, 5% CO2 and 95% humidity and stocks were stored 
in liquid nitrogen before use. 
 
4.3 Chlamydial strains 
 
Two strains of C. pneumoniae were used in the studies. The clinical isolate Kajaani 7 
(K7), was originally isolated from the respiratory tract of a male patient during a C. 
pneumoniae epidemic in military facilities in Finland [226] (I). The other clinical isolate 
CV6, was originally isolated from a vasculature of a patient with coronary artery disease 





4.4. Propagation of C. pneumoniae 
 
C. pneumoniae strains CV6 and K7 were propagated in HL cells. The cells were 
inoculated with C. pneumoniae in an appropriate amount of propagation medium (RPMI 
1640 supplemented with 7.5% FBS, 2 mM L-glutamine, 0.6 µg/ml cycloheximide 
(Sigma-Aldrich), 10 µg/ml gentamicin, 100 mg/ml streptomycin (Sigma-Aldrich) and 
3.75 µg/ml amphotericin B (Sigma-Aldrich) and incubated for 2.5 h at 37 °C. The 
medium was then supplemented to a volume appropriate for the vessel and the cells were 
incubated for additional 70 h. Finally the cells were lysed, cell debris was removed (10 
min, 500 g, 4 °C), EBs were collected by pelleting (60 min, 21 000 g, 4 °C) and 
resuspended into sucrose-phosphate-glutamic acid (SPG) and stored at -80 °C. The EB 
stock titers were determined by infecting the HL cells (see section 4.5) cultured on 
coverslips, with 10-fold serial dilutions. Following a 72-h incubation, C. pneumoniae 
inclusions were stained with a genus-specific anti-LPS antibody (Pathfider, Bio-Rad, 
Hercules, CA, USA) and counted using the EVOS Cell Imaging System (Thermo Fisher 
Scientific). 
 
4.5 Infections (I, II, III, IV) 
 
Cells were seeded into 96-, 24- or 6-well plates at a density specific for each experiment 
(Table 5). The cells, grown as monolayers, were allowed to adhere to the surface 
overnight before infection, while suspension cells were infected immediately after 
seeding. The bacterial inoculum, with variable multiplicities of infection (MOI) (Table 
6), was added to the wells in a small volume (e.g. 200 µl into 24-well) (Table 5) and the 
plates were centrifuged at 550 g, 60 min, at room temperature. The cells were then further 
incubated for 1 h, at 37 °C, after which the inoculum was removed and the test 




Table 5. Cell amounts and C. pneumoniae (Cpn) inoculums used in the studies. 






6 - - 
24 3 × 105 / 1000 200  




6 - - 
24 3–4 × 105 / 1000 1000 
48 5 × 105 / 1000 1000 




6 1 × 106 / 2000 1000 
24 4 × 105 / 1000 200 
96 6 × 104 / 200 100 
 
RAW264.7 
6 4 × 105 / 2000 - 
24 1.5 × 105 200 
96 - - 
 
Table 6. Multiplicities of infections (MOI) used in the experiments in this work. 
Experiment / chapter Cell line MOI 
Cytokine measurement / 4.7 THP-1 mono 2 
NO measurement / 4.8 RAW 264.7 2 
ROS measurement / 4.9 THP-1 macro 1; 5 
GSH measurement / 4.10 THP-1 macro 5 
Foam cell formation / 4.11 THP-1 macro 1 
RAW 264.7 1 
Cholesterol measurement / 4.12 RAW 264.7 5 
Gene expression analysis / 4.14 RAW 264.7 5 
Coculture / 4.15 HL 1 
EB production / 4.16.1 HL 1 
EB exit / 4.16.1 HL 1 
Infectivity / 4.16.2 THP-1 mono 1 
Internalization / 4.16.3 THP-1 mono 1 
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4.6 Host cell viability assay (I, II, III, IV) 
 
Host cell viability during treatment with the test compounds was determined by a 
resazurin viability assay. Cells were seeded into a 96- or 24- well plate and incubated 
with the studied compounds for the specific exposure times of each experiment. 
Resazurin (20 µM) (Sigma-Aldrich) was added to the wells and after a 2-h incubation at 
37 °C fluorescence was recorded at 570/590 nm with the Varioskan LUX plate reader 
(Thermo Fisher Scientific). Cell viability was calculated comparing the fluorescence 
values with the DMSO control. 
 
4.7 Enzyme-linked immunosorbent assay (ELISA) (I) 
 
THP-1 cells were seeded into 48-well plates, infected with C. pneumoniae K7 or exposed 
to the LPS of E. coli and treated with the studied compounds. DuoSet ELISA 
Development Systems kits (R&D Systems, Minneapolis, MN, USA) were used to detect 
target protein concentrations. Secreted cytokines were detected from cell supernatants. 
In general, 96-well plates were first coated with the appropriate capture antibody 
overnight at room temperature. Wells were then washed with buffer containing 0.05% 
Tween® 20 (Sigma-Aldrich) in PBS, blocked by reagent diluent consisting of 1% bovine 
serum albumin (BSA, Sigma-Aldrich) in PBS (1 h), and the samples and standards were 
applied. After a 2-h incubation the biotin-conjugated detection antibody was added, and 
the wells were further incubated for 2 h. The wells were washed and streptavidin-
conjugated horse radish peroxidase (HPR) was added to the wells for 20 min, to bind the 
detection antibody. Finally, substrate solution was added, and the color formed in the 
reaction catalyzed by HRP was detected with the Varioskan LUX plate reader (Thermo 




4.8 Nitrate quantification assay (I) 
 
Nitric oxide (NO) has an extremely short half-life in cells [228], so the quantification of 
nitrate, a metabolite of NO, is conducted instead. Cells were seeded into 24-well plates, 
infected with C. pneumoniae, K7 or CV6, and incubated with the studied compounds. 
Nitrate was quantified using Griess reagent, i.e. 1:1 of 0.1% N-1-napthylethylenediamine 
dihydrochloride (Sigma-Aldrich) and 2% sulfanilamide (Sigma-Aldrich) in 5% 
phosphoric acid, which reacts with nitrite forming a violet product. To this end, 100 µl 
of cell medium and 100 µl of Griess reagent were mixed in 96-well plate and the 
absorbance was recorded at 540 nm with Multiskan Sky microplate spectrophotometer 
(Thermo Fisher Scientific). 
 
4.9 Intracellular ROS detection assay (I, II) 
 
To determine the intracellular ROS levels, THP-1 were seeded into 96-well plate and 
exposed to the studied compounds with or without C. pneumoniae CV6 infection. Cells 
were loaded with dichlorodihydrofluorescein diacetate (DCFH-DA) (Sigma-Aldrich), 
which is taken into the cells and hydrolyzed into DCFH. In the presence of ROS, DCFH 
is oxidized to the fluorescent product dichlorofluorescein (DCF) which was detected 
with Varioskan LUX plate reader (Thermo Fisher Scientific) at 503/523 nm. 
 
4.10 Glutathione quantification (I, II, IV) 
 
The intracellular GSH levels of the cells were determined with the enzymatic recycling 
method, described by Rahman et al. [229]. The method is based on the reaction between 
GSH and 5,5’-dithiobis (2-nitrobenzoic acid) (DTNB), that produces glutathione-TNB 
(GS-TNB) and TNB chromophore, whose amount can be measured. GS-TNB is reduced 
by glutathione reductase (GR), in the presence of NADPH, and GSH is taken back into 
the reaction. The present GSSG (oxidized GSH) is also reduced by GR and thus the total 
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GSH can be determined. THP-1 cells, either monocytes or macrophages, or RAW264.7 
cells were seeded into 6- or 24-well plates and exposed to the studied compounds and/or 
C. pneumoniae CV6, for different time periods. Cells were collected and lysed using 
Triton X-100 (Sigma-Aldrich) and sulfosalicylic acid (Sigma-Aldrich) buffer. GR 
(Sigma-Aldrich) and DTNB (Sigma-Aldrich) were simultaneously added to the reaction, 
and after 30 sec β-NADPH (Sigma-Aldrich) was added. The formed TNB chromophore 
was detected with the Multiskan Sky microplate spectrophotometer (Thermo Fisher 
Scientific) set to 412 nm. GSH concentrations of the samples were obtained by linear 
regression from an 8-point standard curve. 
To normalize the data, total protein concentrations were determined by acetone 
precipitation. 100 µl of the cell lysate samples were heated for 5 min at 95 °C, after 
which 400 µl of ice-cold acetone (Sigma-Aldrich) was added to the sample, followed by 
a 1-h incubation at -20 °C. Proteins were collected by centrifugation at 15 000 g and 
diluted in 100 nM Tris-buffer (Sigma-Aldrich). Concentrations were detected with 
Multiskan Sky microplate spectrophotometer (Thermo Fisher Scientific) using the 
µDrop plate (Thermo Fisher Scientific). 
 
4.11 Oil Red O staining (IV) 
 
THP-1 macrophages or RAW264.7 cells were cultured on 24-well plates, infected with 
C. pneumoniae CV6, and incubated with the studied compounds in the presence of 25 
µg/ml of LDL (Sigma-Aldrich) for 48 h. The cells were then washed with PBS and fixed 
with 4% paraformaldehyde (PFA in PBS) (Santa Cruz Biotechnology, Dallas, TX, 
USA). The fixed cells were washed with Milli-Q water and incubated 5 min with 60% 
of isopropanol (Rathburn Chemicals, Walkerburn, Scotland). The cells were allowed to 
dry, and Oil Red O solution containing 350 mg of Oil Red O (Sigma-Aldrich) and 100 
ml of 100% isopropanol, diluted 3:2 with Milli-Q water was added to the cells for 10 
min. The dye was removed and the cells were washed with Milli-Q water until the 
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washing solution was clear. The cells and lipid droplets were analyzed under the EVOS 
cell imaging systems microscope (Thermo Fisher Scientific) using 20× magnification. 
 
4.12 Free cholesterol and cholesteryl ester quantification (IV) 
 
RAW264.7 macrophages were seeded into 24-well plates, infected with C. pneumoniae 
CV6 and incubated with the studied compounds, in the presence of 25 µg/ml LDL 
(Sigma-Aldrich). The ratio of free cholesterol and cholesteryl ester was determined from 
the cells with Amplex© Red cholesterol assay kit (Invitrogen/Thermo Fisher Scientific) 
by a method modified from the manufacturer’s instructions. In brief, the cells were fixed 
with 2% PFA and washed with PBS. Lipids were extracted by incubating the cells for 
30 min at 4 °C with ethanol. Samples were prepared by mixing 40 μl of the ethanol-lipid 
solution and 60 μl of the supplied reaction buffer. For detecting the amount of total 
cholesterol, 50 μl of samples were mixed with 50 μl of assay solution (150 μM Amplex© 
Red solution, 1 U/ml HRP, 1 U/ml cholesterol oxidase, 0.1 μM cholesterol esterase and 
reaction buffer). For the quantification of free cholesterol, the sample was incubated with 
a similar assay solution but without cholesterol esterase. Both solutions were incubated 
30 min at 37 °C and the fluorescence was recorded with Varioskan Lux plate reader 
(Thermo Fisher Scientific) at 540/590 nm. The cholesterol concentrations were 
determined from a six-point standard curve. The fraction of esterified cholesterol was 
calculated based on the concentrations of the free and the total cholesterol. 
 
4.13 Quantitative PCR (II, III) 
 
Genomic DNA of the cells was extracted with GeneJet Genomic DNA purification kit 
(Thermo Fisher Scientific) according to the manufacturer’s instructions. The DNA 
concentrations were measured using NanoDrop (Thermo Fisher Scientific) or Multiskan 
Sky (Thermo Fisher Scientific) using the µDrop plate (Thermo Fisher Scientific) and 20 
ng of DNA was added to each PCR reaction. The C. pneumoniae CV6 genome copy 
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numbers were quantified based on the ompA gene [230] using Step One Plus Real-Time 
PCR system (Thermo Fisher Scientific). Experiments were carried out using Fast SYBR 
Green master mix (Thermo Fisher Scientific) and 20 µl reactions were performed in 96-
well MicroAmp optical plates (Thermo Fisher Scientific). Conditions in the PCR thermal 
cycler were 95 °C for 20 s and 40 cycles of 95 °C for 3 s and 60 °C for 30 s. C. 
pneumoniae genome equivalent (GE) quantity was determined comparing the results to 
a 5-point standard curve made from a chlamydial stock solution with known titer. 
 
4.14 Reverse transcription PCR (IV) 
 
RAW264.7 cells were seeded into 24-well plates and treated with the studied 
compounds, with or without C. pneumoniae CV6 infection. Total RNA of the cell culture 
samples was purified using PureLink RNA Mini Kit (Thermo Fisher Scientific) 
according to the manufacturer’s instructions. RNA was then used as a template for 
cDNA synthesis, which was performed using RevertAid First Strand cDNA Synthesis 
Kit (Thermo Fisher Scientific). cDNA concentrations were measured with NanoDrop 
(Thermo Fisher Scientific) and 20 ng were used per PCR reaction. The expression of 
different genes was quantified with the Step One Plus Real-Time PCR system (Thermo 
Fisher Scientific) and values were normalized to expression of the housekeeping gene 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Thermo Fisher Scientific). The 
results for comparative ΔCt RT-PCR were obtained using the 2^-ΔΔCt method. In the 
data analysis, fold changes (RQ values) below 0.5 and above 2 were considered as 











ompA genomic C. pneumoniae F: 5’- TCC GCA TTG CTC AGC C -3’ 
R: 5’- AAA CAA TTT GCA TGA AGT CTG AGA A -3’ 
CD36 cDNA mouse F: 5’- TCG GAA CTG TGG GCT CAT TG -3’ 
R: 5’- CCT CGG GGT CCT GAG TTA TAT TTT C -3’ 
PPARγ cDNA mouse F: 5’- GAC ATC CAA GAC AAC CTG CTG -3’ 
R: 5’- GCA ATC AAT AGA AGG AAC ACG -3’ 
GCLc cDNA mouse F: 5’- ATG TGG ACA CCC GAT GCA GTA TT -3’ 
R: 5’- TGT CTT GCT TGT AGT CAG GAT GGT TT -3’ 
GCLm cDNA mouse F: 5’- GCC ACC AGA TTT GAC TGC CTT T -3’ 
R: 5’- CAG GGA TGC TTT CTT GAA GAG CTT -3’ 
ABCA1 cDNA mouse F: 5’- CAA CTA CAA AGC CCT CTT TG -3’ 
R: 5’- CTT GGC TGT TCT CCA TGA AG -3’ 
GGT-1 cDNA mouse F: 5’- GGA GAG AGT TTC TGC CCA TCC ATA C -3’ 
R: 5’- GCG GCT GGG TGG GTG GT -3’ 
F, forward; R, reverse. All the primers used against mouse cDNA were checked with 
Primer-blast (NCBI) to confirm the absence of cross-recognition in C. pneumoniae. 
 
 
4.15 Coculture assay (III) 
 
HL cells were seeded into a 24-well plate (3 × 105 cells/well) and infected with C. 
pneumoniae CV6. At 67 h post infection the HL cells were washed with PBS and the 
same number of THP-1 monocytes were added. Studied compounds were added to the 
wells and the cells were incubated together for 5 h. THP-1 monocytes were pipetted from 
the wells, centrifuged and resuspended in 100 µl buffer solution containing 1% BSA and 
5 mM ethylenediaminetetraacetic acid (EDTA, Sigma-Aldrich) in PBS. A solution of 
1:100-diluted biotin-conjugated human leukocyte antigen (HLA-A2) antibody 
(Biolegend, CA, USA) was added and the cells were incubated on ice for 15 min, 
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followed by a washing with the buffer. The cells were then incubated on ice with a 
solution of 1:100-diluted streptavidin-conjugated MojoSort magnetic nanobeads 
(Biolegend). After that, the cells were washed and resuspended in 500 µl of the buffer. 
The cells were loaded into MidiMACS magnetic separator system (Miltenyi Biotech, 
CA, USA), washed with 4 x 3 ml of the buffer, eluted and counted. The summary of cell 
separation protocol is presented in Figure 4. 
     
 
Figure 4. Coculture cell separation protocol using MACS magnetic bead separation 
system [231].  
 
 
4.16 Infectivity assays (III) 
 
4.16.1 Quantification of C. pneumoniae EB production and EB exit 
 
HL cells were seeded into 24-well plates, infected with C. pneumoniae CV6, and 
incubated for 67 h at 37 °C. The studied compounds were added to the culture and the 
cells were incubated for additional 5 h at 37 °C. C. pneumoniae EBs released from the 
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cells were collected with the supernatant and the EBs remaining in the cells were 
harvested by scraping the cells and lysing them with glass beads. Both the EBs from the 
supernatants and from the cell lysates were inoculated onto fresh HL monolayer. After 
the EBs were allowed to internalize into the cells for 3 h, the cells were collected, and 
total cellular DNA was extracted with GeneJet Genomic DNA purification kit (Thermo 
Fisher Scientific). The C. pneumoniae genome copy numbers in the cells were quantified 
as described under the section 4.13. 
 
4.16.2 C. pneumoniae EB infectivity assay 
 
Purified C. pneumoniae CV6 EBs from a stock suspension were incubated with the 
studied compounds on ice for 2 h. THP-1 monocytes were added and the suspension was 
incubated for 2 h at 37 °C. The monocytes were collected in PBS and lysed, after which 
DNA was extracted with GeneJet Genomic DNA purification kit (Thermo Fisher 
Scientific). The C. pneumoniae genome copy numbers in the cells were quantified as 
described under the section 4.13. 
 
4.16.3 C. pneumoniae EB internalization assay 
 
A suspension of THP-1 cells, C. pneumoniae CV6 EBs and the studied compounds was 
incubated together for 2 h at 37 °C. The cells were washed and collected in PBS and 
DNA was extracted with GeneJet Genomic DNA purification kit (Thermo Fisher 
Scientific). The C. pneumoniae genome copy numbers internalized into the cells were 






4.17 Statistical analyses 
 
Data were analyzed using the IBM SPSS Statistics v. 25 software (IBM, Armonk, NY, 
USA). The comparisons of group means were performed either by using Student’s t-test, 
with Bonferroni correction where appropriate, or one-way ANOVA with Dunnett’s T 
and Games-Howell post hoc tests for equal and unequal variance, respectively. P-values 
below 0.05 were considered as statistically significant and are indicated in the figures as 







5.1 The impact of schisandrin lignans on host cell viability (I, II, III, IV) 
 
The impact of schisandrin lignans on host cell viability was studied with a resazurin 
viability assay. The viability of THP-1 monocytes, THP-1 macrophages, and RAW264.7 
cells is presented as viability percentage in Table 8. No reduction in THP-1 monocyte 
cell viability was observed after 24 or 48-h exposure to any of the compounds or 
concentrations. The maximum incubation time in experiments involving THP-1 
monocytes is 48 h. Neither schisandrin nor schisandrin C reduced the THP-1 
macrophage cell viabilities, but schisandrin B caused a statistically significant reduction. 
This should be taken into consideration when evaluating the results concerning 
schisandrin B in THP-1 macrophages. Schisandrin B at a 50 µM concentration reduced 
also the RAW264.7 cell viability significantly after a 72-h incubation. Thus, most of the 
experiments with RAW264.7 cells were performed with a maximum of 48-h incubation. 
In the experiments with 72-h incubation, the possible host cell toxicity should be 
considered. The viability of HL cells after exposure to schisandrin lignans has been 











Table 8. The impact of schisandrin lignans on host cell viability. 
Cell line Compound Viability-% 





Schisandrin 25 µM 103 ± 15 145 ± 5 nd 
Schisandrin 50 µM 110 ± 7 127 ± 3 nd 
Schisandrin B 25 µM 163 ± 9 152 ±7       nd 
Schisandrin B 50 µM 103 ± 15 136 ± 5 nd 
Schisandrin C 25 µM 130 ± 3 128 ± 5 nd 





Schisandrin 25 µM 118 ± 8 105 ± 7 93 ± 2 
Schisandrin 50 µM 106 ± 7 119 ± 7 92 ± 6 
Schisandrin B 25 µM 80 ± 5 70 ± 8 80 ± 4* 
Schisandrin B 50 µM 67 ± 3* 50 ± 5* 69 ± 8 
Schisandrin C 25 µM 89 ± 7 78 ± 7 111 ± 6 





Schisandrin 25 µM nd 98 ± 1 100 ± 3  
Schisandrin 50 µM nd 99 ± 2 95 ± 2 
Schisandrin B 25 µM nd 87 ± 1 80 ± 4 
Schisandrin B 50 µM nd 61 ± 3 36 ± 3* 
Schisandrin C 25 µM nd 103 ± 3 97 ± 1 
Schisandrin C 50 µM nd 101 ± 2 90 ± 1 
nd, not determined. Viability studies were carried out with resazurin assay and the 
viability percentage are presented as mean ± SEM. Statistical significances were 
determined by Student’s t-test with Bonferroni correction and they are presented as 
marks of P values: < 0.05: *; < 0.01: **; < 0.001: ***, n ≥ 3. Data from THP-1 monocytes 
are originally presented in publication I, THP-1 macrophages in publication II and 
RAW264.7 in publication IV. 
 
 
5.2 The impact of schisandrin lignans on inflammatory cytokine 
production in THP-1 monocytes (I) 
 
The impact of schisandrin lignans on inflammatory cytokine production was determined 
in THP-1 monocytes infected with C. pneumoniae K7 or challenged with E. coli LPS 
using ELISA. The concentrations of three interleukins, IL-6, IL-10 and IL-12 were 
detected. As a response to C. pneumoniae infection, only the levels of IL-12 were 
elevated in THP-1 monocytes (Figure 5). The LPS of E. coli, which is considered more 
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immunogenic than C. pneumoniae LPS, elevated both IL-12 and IL-6 levels. The IL-12 
elevation was approximately 20-fold higher in the LPS-stimulated samples than in C. 
pneumoniae samples. Neither exposure elevated the IL-10 levels in THP-1 monocytes.  
Schisandrin had no effect on the levels of any of the studied interleukins. Schisandrin B, 
on the other hand, decreased the secretion of all the studied interleukins compared to the 
LPS or C. pneumoniae controls (CPN). At 25 µM, it reduced the IL-12 levels by 40% 
(LPS) and 69% (CPN). The IL-6 levels were reduced by 44% (LPS). At 50 µM 
concentration the reduction in IL-12 levels was 89% (LPS) and 68% (CPN), while the 
reduction in IL-6 levels was 49% (LPS). Schisandrin C also decreased the LPS induced 
IL-12 production at 50 µM concentration by 68%, and C. pneumoniae-induced IL-12 at 
25 µM by 65%. IL-6 (LPS) was reduced by 32% at 25 µM concentration and 35% at 50 
µM concentration.  
 
 
Figure 5. IL-12 and IL-6 production in THP-1 monocytes after LPS and C. pneumoniae 
exposure and treatment with schisandrin, schisandrin B and schisandrin C. Data are 
presented as secretion index, compared to LPS or C. pneumoniae infection control, as 
mean ± SEM. Statistical significances were determined using ANOVA and Games-
Howell post hoc test (p : < 0.05: *; < 0.01: **; < 0.001: ***), n ≥ 4. Data are originally 
presented in publication I.  
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5.3 The impact of schisandrin lignans on NO production of the cells (I)  
 
The nitrate levels, indicative of NO, were quantified in THP-1 monocytes using the 
Griess reagent. The cells were treated with 1 µg/ml of LPS of E. coli and the nitrate 
levels were determined spectrophotometrically. 
There was no elevation of nitrate levels observed in THP-1 cells, neither monocytes nor 
macrophages, even after exposure to high levels of LPS or C. pneumoniae CV6 infection 
at any time point between 4 h and 72 h (data not shown). Some controversial data exist 
regarding the topic, but there are studies that are in line with our results [232, 233] that 
NO is indeed not produced in THP-1 cells. 
Further nitrate production studies were thus conducted with RAW264.7 macrophage 
cells. The cells were treated with 1 µg/ml of LPS and they were incubated with 50–100 
µM of schisandrin, schisandrin B and schisandrin C, with luteolin (10 µM) as the 
positive control. The results shown in Figure 6A demonstrate that schisandrin B and 
schisandrin C inhibited the LPS-induced nitrate production after a 24-h exposure by 86% 
and 42%, respectively. 
The impact of schisandrin lignans (25 µM and 50 µM) was also studied in RAW264.7 
macrophages infected with C. pneumoniae and compared to the LPS-induced nitrate 
production. The cells were incubated with schisandrin lignans for 24, 48 and 72 h. C. 
pneumoniae infection elevated the nitrate levels significantly compared to the untreated 
control (Figure 6B). Schisandrin had no effect on C. pneumoniae-induced nitrate levels, 
but schisandrin B reduced them at both concentrations. At 24, 48 and 72 h, 25 µM 
schisandrin B had reduced the levels by 45%, 50% and 50%, respectively. Treatment at 




               
 
      
Figure 6. Nitrate production in RAW264.7 cells after A) LPS exposure and B) C. 
pneumoniae infection. The cells were treated with schisandrin lignans and luteolin after 
the induction of nitrate production. Data are presented as mean ± SEM. Statistical 
significances were determined using ANOVA and Games-Howell post hoc test (p < 







5.4 ROS production in THP-1 cells (I, II) 
 
5.4.1 The impact of C. pneumoniae infection and LPS exposure on ROS levels 
 
The impact of C. pneumoniae CV6 infection on the intracellular ROS production of 
THP-1 macrophages was studied. The cells were infected at MOI1 and MOI5 and treated 
with 1 µg/ml of LPS of E. coli. After 24, 48 or 72 h incubation the cells were exposed to 
DCFH-DA for 30 min and fluorescence was detected. Results were compared to non-
infected control. C. pneumoniae elevated the ROS levels after 48 and 72 h and the 
elevation was MOI-dependent (Figure 7). After 48 h the increase was 18% (MOI1) and 
26% (MOI5), and after 72 h it was 25% (MOI1) and 34% (MOI5). LPS of E. coli also 
elevated the ROS levels after 48 h (75%) and 72 h (47%). 
 
       
Figure 7. ROS levels in THP-1 macrophages after 24, 48 and 72 h exposure to 1 µg/ml 
of LPS of E. coli, MOI1 or MOI5 C. pneumoniae infection. Data are presented as mean 
± SEM. Statistical significance was determined using Student’s t-test with Bonferroni 




5.4.2 The impact of schisandrin lignans on basal ROS levels 
 
The impact of schisandrin lignans on the basal ROS production of THP-1 monocytes 
and macrophages was additionally studied. In monocytic cells, the immediate ROS 
production after lignan exposure was studied. The cells were loaded with DCFH-DA, 
after which they were treated for 1 h. As shown in Figure 8A, schisandrin at both 25 and 
50 µM concentrations elevated the ROS levels significantly; 25 µM by 43% and 50 µM 
by 50%. There were no differences in the quantified ROS levels after schisandrin B and 
schisandrin C exposure compared to the vehicle control. 
In THP-1 macrophages, the impact of schisandrin lignans on intracellular ROS 
production was determined at 4 to 72 h. There were no differences after 4–48 h of lignan 
treatment, but at 72 h schisandrin and schisandrin C had significantly elevated the ROS 
levels (Figure 8B). Schisandrin elevated the levels by 31% at both concentrations and 




              
                                
 
Figure 8. Impact of schisandrin lignans on ROS levels in THP-1 cells: A) 30 min 
exposure with THP-1 monocytes and B) 48 and 72-h incubation with THP-1 
macrophages. Data are presented as mean ± SEM. Statistical significance was 
determined using Student’s t-test with Bonferroni correction (p < 0.05: *; < 0.01: **; < 
0.001: ***), n ≥ 4. Data from THP-1 monocytes is originally presented in publication I 






5.4.3 The impact of schisandrin lignans on ROS levels in C. pneumoniae-
infected and LPS-treated THP-1 macrophages 
 
The impact of schisandrin lignans on ROS levels was determined in THP-1 macrophages 
after LPS (E. coli) exposure (Figure 9A) and C. pneumoniae CV6 infection (Figure 9B). 
In LPS-treated cells, schisandrin B decreased the levels significantly at both 
concentrations, by 17% (25 µM) and 56% (50 µM), and schisandrin C decreased the 
levels at 50 µM by 32%. Schisandrin had no effect on the LPS-induced ROS levels. On 
the other hand, only 50 µM schisandrin B decreased the C. pneumoniae-induced ROS 
production by 43% (48 h) and 64% (72 h). THP-1 macrophage viability was significantly 
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Figure 9. The impact of schisandrin lignans on A) LPS-induced and B) C. pneumoniae-
induced ROS production. Data are presented as mean ± SEM. Statistical significance 
was determined using Student’s t-test with Bonferroni correction (p < 0.05: *; < 0.01: 
**; < 0.001: ***), n ≥ 4. Data from LPS-induced ROS production are unpublished and 









5.5 The impact of schisandrin lignans on cellular GSH levels (I, II, IV) 
 
5.5.1 The impact on basal GSH levels 
 
The effect of schisandrin lignans on intracellular GSH was determined in THP-1 cells, 
both monocytes and macrophages, and in RAW264.7 macrophages. All the results were 
compared to the vehicle control and the levels in both macrophages were normalized to 
the total protein amount of the samples. 
The cells were cultured in 6-well plates and exposed to schisandrin lignans for different 
time periods. Total GSH levels in the cells were detected using enzymatic recycling 
method with DTNB. In THP-1 monocytes, schisandrin B decreased the levels after 24 h 
by 49% (50 µM) and after 48 h by 54% (25 µM) and 73% (50 µM) (Figure 10). 
Schisandrin C (50 µM) also decreased the levels by 50% after 48 h. Furthermore, 
schisandrin B and C had significantly decreased the GSH-levels already after 4 h 
incubation (data not shown). Schisandrin had no significant effect on GSH levels in 
THP-1 monocytes. 
In THP-1 macrophages, schisandrin B decreased the levels after 24 h by 31% (25 µM) 
and after 48 h by 76% (25 µM) and 91% (50 µM). Schisandrin (50 µM) reached a 
significant decrease (47%) by the 24 h time point. Schisandrin C also seemed to decrease 
the GSH levels in THP-1 macrophages, but the effect was not statistically significant.  
In RAW264.7 macrophages, the impact of schisandrin lignans was different compared 
to THP-1 cells. Schisandrin at 50 µM decreased the GSH levels 54% and 73% after 48 
h and 72 h, respectively. Schisandrin C elevated the levels after 48 h by 76% (25 µM) 
and 110% (50 µM). The higher concentration elevated the levels significantly also after 
72 h incubation (64%). While schisandrin B seemed to elevate the levels at each time 




Figure 10. The impact of schisandrin lignans on basal GSH levels in THP-1 monocytes 
and macrophages and RAW264.7 macrophages. The cells were incubated with the 
compounds for 24 and 72 h and the GSH levels were compared to vehicle control 
(DMSO). Data are presented as mean ± SEM. Statistical significance was determined 
using Student’s t-test with Bonferroni correction (p < 0.05: *; < 0.01: **; < 0.001: ***), 
n ≥ 4. Data from THP-1 monocytes are originally presented in publication I, from THP-
1 macrophages in publication II and from RAW264.7 in publication IV. 
 
5.5.2 The impact of schisandrin lignans on the GSH levels of C. pneumoniae-
infected THP-1 macrophages 
 
The impact of C. pneumoniae CV6 infection on GSH levels in THP-1 macrophages and 
the effects of schisandrin, schisandrin B and schisandrin C on those levels was next 
determined. The cells were infected with MOI1 and MOI5 for 48 and 72 h. While MOI1 
elevated the GSH levels significantly at 72 h incubation, MOI5 did so already at 48 h, 
but the effect was mitigated later. Schisandrin decreased the C. pneumoniae-induced 
GSH levels at 25 and 50 µM concentrations after a 72-h incubation by 62% and 57%, 
respectively (Figure 11). Schisandrin B decreased the levels at both concentrations after 
48 (71% and 99%) and 72 h (69% and 84%), while schisandrin C decreased the levels 
at both concentrations after 72 h incubation by 65% and 55%, respectively. 
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Figure 11. The impact of schisandrin lignans on the GSH levels of C. pneumoniae-
infected THP-1 macrophages. The cells were incubated with the compounds for 48 and 
72 h and the GSH levels are compared to vehicle control (DMSO). Data are presented 
as mean ± SEM. Statistical significance was determined using Student’s t-test with 
Bonferroni correction (p < 0.05: *; < 0.01: **; < 0.001: ***), n ≥ 4. Data are originally 
presented in publication II. 
 
5.6 The impact of schisandrin lignans on C. pneumoniae-induced foam 
cell formation (IV) 
 
RAW264.7 macrophages and THP-1 macrophages were infected with C. pneumoniae 
CV6 and treated with 50 µM schisandrin lignans in the presence of LDL for 48 h. The 
cells were stained with Oil Red O dye to examine the resulting foam cell formation. The 
effects of the glutathione biosynthesis inhibitor buthionine sulfoximine (BSO) and the 
MAPK inhibitors SP600125 (JNK1/2) and SB202190 (p38) on the foam cell formation 
was also studied. C. pneumoniae induced foam cell formation in both cell lines (Figure 
12A and B). BSO increased the foam cell formation in RAW264.7 cells (Figure 12A), 
which is in line with earlier reports [234]. Schisandrin had no effect on lipid 
accumulation, but schisandrin B inhibited it very efficiently in both cell lines. 





not completely in THP-1 cells (Figure 12B). SP600125, a JNK1/2 inhibitor, blocked the 
foam cell formation in RAW264.7 cells (Figure 12A) but not in THP-1 cells (Figure 
12B). SB202190, a p38 kinase inhibitor, instead seemed to decrease lipid droplets in 





Figure 12. Impact of schisandrin lignans and MAPK inhibitors on macrophage foam cell 
formation in the presence of LDL in A) RAW264.7 cells and B) THP-1 cells. Lipid 





5.7 The impact of schisandrin lignans on total cholesterol and cholesteryl 
ester levels in RAW264.7 cells (IV) 
 
The total cholesterol and cholesteryl ester levels were determined with Amplex© red 
reagent in infected RAW264.7 macrophages, treated with schisandrin lignans (50 µM) 
and BSO (250 µM) in the presence of 25 µg/ml of LDL, after a 48-h exposure. According 
to these data, BSO elevated the total cholesterol levels by 19.4% (p=0.004) while 
schisandrin B decreased the levels by 18.9% (p=0.005), as compared to the infection 
control (Figure 13). The cholesteryl ester levels were calculated by subtracting the free 
cholesterol level from that of the total cholesterol. Schisandrin B and schisandrin C 
seemed to lower the cholesteryl ester levels (21.9% and 19.7%, respectively), although 
these effects did not reach statistical significance. 
 
 
            
Figure 13. The impact of schisandrin lignans on total cholesterol and cholesteryl ester 
levels in RAW264.7 macrophages. The cells were incubated with schisandrin lignans 
for 48 h and cholesterol levels were compared to the infection control. Data are presented 
as mean ± SEM. Statistical significance was determined using one-way ANOVA with 
Dunnett’s T post hoc test (p < 0.05: *; < 0.01: **; < 0.001: ***), n = 6. Data are presented 
in publication IV. 
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5.8 The impact of schisandrin lignans on the gene expression profile in 
RAW264.7 macrophages (IV) 
 
The impact of schisandrin lignans on the expression of an array of GSH and lipid 
metabolism-related genes in RAW264.7 macrophages was studied using reverse 
transcription PCR. The cells were incubated for 48 h in the presence of 50 µM 
schisandrin, schisandrin B and schisandrin C. The expression levels of PPARγ, CD36, 
ABCA1, GCLc, GCLm and GGT-1 were detected and compared to GAPHD 
housekeeping gene expression. The impact of C. pneumoniae CV6 infection and the 
concomitant administration of schisandrin lignans was also studied by infecting the cells 
with a MOI5 and incubating them for 48 h.  
PPARγ is a nuclear receptor which regulates lipid and glucose metabolism and its 
expression is changed in several pathological conditions, such as atherosclerosis. CD36 
is a scavenger receptor that imports lipids, such as oxidized LDL and fatty acids, into 
the cells. ABCA1, on the other hand, mediates the efflux of cholesterol and 
phospholipids out of the cells. GCLc and GCLm are the two domains (catalytic and 
modifier) of the enzyme that is synthetizing GSH. GGT-1 is a protein that breaks up the 
extracellular GSH and it is a key regulator in the GSH synthesis. 
The isolated effect of C. pneumoniae infection was first characterized to provide a 
baseline for the experimental treatment study. There were no changes in the gene 
expression after C. pneumoniae (MOI5) infection. However, when the infection was 
performed in presence of LDL, the PPARγ expression decreased statistically 
significantly, by RQ of 0.4 (Table 9). The expression levels of the other genes of interest 
remained unchanged. 
The impact of schisandrin lignans on the gene expression of non-infected RAW264.7 
cells is presented in Table 10. Schisandrin B and C elevated the expression of PPARγ by 
the relative quantification (RQ) of 4.7 and 2.3, respectively, while all three lignans had 
an effect on the ABCA1 expression: schisandrin inhibited it (RQ 0.4) and schisandrin B 
and C increased it (RQ 15.2 and 4.0, respectively). Schisandrin B also increased the 
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expression of GSH metabolism-related genes GCLc, GCLm and GGT-1 by RQ of 2.2, 
2.6 and 4.5, respectively. 
When the cells were concomitantly exposed to C. pneumoniae and the schisandrin 
lignans, the changes in gene expressions were almost similar to the samples only exposed 
to the lignans, with ABCA1 being the most affected one (Table 10). Schisandrin 
downregulated ABCA1 by a RQ of 0.3, whereas schisandrin B and schisandrin C caused 
a considerable upregulation, (RQ 10.1 and 5.3, respectively). 
 
Table 9. The impact of C. pneumoniae infection on the gene expression profile in 
RAW264.7 cells. 
Gene Effect on expression RQ value 
PPARγ decreasing 0.4 ± 0.08* 
CD36 - 0.9 ± 0.04 
ABCA1 - 1.8 ± 0.4 
GCLc - 0.8 ± 0.06 
GCLm - 0.9 ± 0.09 
GGT-1 - 0.6 ± 0.05 
The amplification of each gene was compared to the housekeeping gene GAPHD. 
Relative quantification (RQ) values were obtained using the 2^-ΔΔCt method (Ct: cycle 
threshold). RQ values are presented (± SEM), and changes above 2 and below 0.5 were 
considered as significant and marked with bolding. Statistical significances were 
determined according to ΔCt with Student’s t-test (p < 0.05: *; < 0.01: **; < 0.001: ***), 




Table 10. The impact of schisandrin lignans on the expression of lipid and GSH 
metabolism genes in RAW264.7 cells, with and without C. pneumoniae infection. 
Gene Compound RQ value /  
basal 
RQ value /  
infection 
PPARγ Schisandrin 1.5 ± 0.5 1.2 ± 0.3 
Schisandrin B 4.7 ± 0.8** 6.5 ± 0.3** 
Schisandrin C 2.3 ± 0.5 2.0 ± 0.5 
CD36 Schisandrin 0.9 ± 0.2 0.8 ± 0.04 
Schisandrin B 1.6 ± 0.3 2.2 ± 0.3 
Schisandrin C 1.7 ± 0.5 2.0 ± 0.6 
ABCA1 Schisandrin 0.4 ± 0.1 0.3 ± 0.05* 
Schisandrin B 15.2 ± 1.3** 10.1 ± 3.4** 
Schisandrin C 4.0 ± 0.8 5.3 ± 1.9* 
GCLc Schisandrin 1.2 ± 0.6 1.4 ± 0.05 
Schisandrin B 2.2 ± 0.1* 2.5 ± 0.3** 
Schisandrin C 1.5 ± 0.3 1.2 ± 0.2 
GCLm Schisandrin 1.5 ± 0.2 1.6 ± 0.2 
Schisandrin B 2.6 ± 0.2** 3.8 ± 0.4*** 
Schisandrin C 1.9 ± 0.3* 1.8 ± 0.4* 
GGT-1 Schisandrin 2.1 ± 0.9 1.2 ± 0.2 
Schisandrin B 4.5 ± 0.7* 4.4 ± 1.2** 
Schisandrin C 1.2 ± 0.3 1.4 ± 0.4 
The amplification of each gene was compared to the housekeeping gene GAPHD. 
Relative quantification (RQ) values were obtained using the 2^-ΔΔCt method (Ct: cycle 
threshold). RQ values are presented (± SEM) and changes above 2 and below 0.5 were 
considered as significant and marked with bolding. Statistical significances were 
determined according to ΔCt with ANOVA and Dunnett’s T post hoc test (p < 0.05: *; 




5.9 The study of C. pneumoniae transfer from respiratory epithelium to 
monocytes (III) 
 
C. pneumoniae is known to transfer from its primary site of an infection, respiratory 
epithelium, to other sites of the body, and by that mechanism to contribute to the 
development of chronic inflammatory diseases, such as atherosclerosis. A coculture 
model with HL cells and THP-1 monocytes was developed, in which the transfer of 
bacteria between the epithelial cells and phagocytes can be studied.  
HL cell monolayers were infected with C. pneumoniae CV6. At the end of the infection 
cycle (67 h post infection), THP-1 cells and the studied compounds were added to the 
culture with the HL cells. The cells were incubated together for 5 h, after which THP-1 
cells were selectively collected using the MACS magnetic cell separation system. 
Finally, the C. pneumoniae genome copy numbers were detected using qPCR. 
The compounds used in the developing the system were the MAPK inhibitors SP600125 
(JNK1/2 inhibitor), SB203580 (p38 inhibitor) and FR180204 (ERK inhibitor) whose 
targets are known to be affected by C. pneumoniae infection. SP600125 decreased the 
transfer of C. pneumoniae between the cell lines by 69%, SB203580 by 54% and 
FR180204 by 37%, as compared to the untreated infection control (Figure 13). 
The possible mechanisms by which the MAPK inhibitors block the transfer of C. 
pneumoniae were examined. The results of the different infectivity studies are presented 
in Figure 14. The MAPK inhibitors did not have any effect on C. pneumoniae EB 
production inside the epithelial cells, but SP600125 significantly increased the release 
of the EBs from the cells. In addition, EBs were pre-treated with the MAPK inhibitors, 
whose influence on the EB infectivity was then examined. No effect on infectivity was 
observed. When THP-1 cells were incubated with MAPK inhibitors and C. pneumoniae 
EBs for 2h, the compounds SP600125 and SB203580 decreased the C. pneumoniae 
internalization by 40% and 38%, respectively. FR180204 also decreased the 
internalization by 28% but the decrease was not statistically significant. 
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Figure 13. Impact of MAPK inhibitors on the transfer of C. pneumoniae between HL 
epithelial cells and THP-1 monocytes. C. pneumoniae genome copy numbers (GE) 
inside THP-1 monocytes were determined by qPCR. Data are presented as mean ± SEM. 
Statistical significance was determined using ANOVA and Dunnett’s T post hoc test (p 




Figure 14. Impact of MAPK inhibitors on the production, release, infectivity and 
internalization of chlamydial elementary bodies (EB). C. pneumoniae genome copy 
numbers (GE) were determined by qPCR. Data are presented as mean ± SEM. Statistical 
significance was determined using ANOVA and Dunnett’s T post hoc test (p < 0.05: *; 






This thesis focused on antichlamydial lead compound profiling in monocyte and 
macrophage cell models. The compounds of interest were three schisandrin lignans, 
schisandrin, schisandrin B and schisandrin C, which are dibenzocyclooctadiene lignans 
isolated from Schisandra chinensis berries. The studies involved the human lung cell 
line (HL); THP-1 monocytic cell line, which was also differentiated into macrophage 
like cells; and RAW264.7 murine macrophage cell line. 
Since Chlamydia pneumoniae is an obligate intracellular bacterium, all biological 
studies concerning the bacterium need to be done by infecting mammalian cells. Most 
cell lines used in Chlamydia-related drug research and susceptibility screenings are 
epithelial cell lines; such as HeLa, Hep2 and HL cells; as well as endothelial cell lines, 
such as HUVECs. These are permissive cell lines in which Chlamydia can replicate 
effectively and maintain a productive infection. 
In vivo, C. pneumoniae can disseminate from the primary site of an infection, namely 
the respiratory tract, to other body sites through PBMCs [3, 18]. Via this route, bacteria 
can infect various tissues in the body, and these infections have been related to many 
chronic inflammatory diseases [235].  
From a therapeutic point of view, PBMCs are of high importance because the infection 
in these cells is in a persistent stage [8], and it is thus very difficult to treat with 
conventional antibiotics. Being able to eliminate the pathogen in these cells and to 
prevent the changes induced in PBMC behavior would be important for stopping the 
pathological processes related to inflammatory diseases. 
The persistence of C. pneumoniae is a massive problem in the clinic. Persistent infections 
remain unnoticed due to their minor or even absent symptoms, but on a cellular level, 
persistent infections still affect infection sites by maintaining the inflammatory processes 
in their surroundings [7]. Still, even if persistent Chlamydia were readily diagnosed, 
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there are no effective drugs against such form of infection, since all conventional 
antibiotics are ineffective against it. 
In this work, I used the C. pneumoniae strains K7 and CV6 in persistent infection models 
to study their effects on monocytic and macrophage cell lines. No data were previously 
available on the impacts of schisandrin lignans on the persistent C. pneumoniae-induced 
functions in the cell lines used in this work. As another contribution to compound 
profiling studies I developed a new platform for studying the transfer of the infection 
between epithelial cells and phagocytes, which can be used in the preclinical drug studies 
of antichlamydial compounds. 
Several antichlamydial compounds have been studied during the past decades, including 
already approved drugs such as statins [184], heparins [185] and rapamycin [236], as 
well as investigational compounds such as plant polyphenols [196], betulin derivatives 
[237], 2-arylbenzimidazoles [186] and β2,2-amino acid derivatives [31]. Antibiotic 
treatments against C. pneumoniae and their impact on coronary artery disease and 
multiple sclerosis have also been studied previously. 
Schisandra chinensis lignans have been studied in our laboratory for several years since 
they demonstrated antichlamydial activity in inhibition studies against C. pneumoniae 
and C. trachomatis in permissive cell lines. Compounds were chosen into these studies 
because they showed activity also in monocytes and macrophages where C. pneumoniae 
infection is persistent. 
The C. pneumoniae cellular components in PBMCs are recognized by the host cells via 
the pattern-recognizing Toll like receptors (TLRs) and Nod-like receptors (NLRs) [133, 
141]. The receptors are localized in cell membrane and cytoplasm, respectively, where 
they recognize various structures in microorganisms and initiate the immune responses. 
There are 10 members in TLR family identified in human cells (TLR1–10) and 12 in 
mice (TLR1–9, TLR11–13) [238]. Concerning C. pneumoniae recognition, TLR2 and 
TLR4 are the most relevant. It is reported that C. pneumoniae induces inflammatory 
molecule production through the TLR2 signaling cascade in 293HEK cells, dendritic 
80 
 
cells [85] and in macrophages [85, 132]. TLR4 has also been reported to initiate the C. 
pneumoniae-induced transactions in dendritic cells, human monocytes [239] and murine 
models [240]. TLR3 activation in the HCAEC primary cell line has also been suggested 
[241]. Most likely, various TLRs, at least TLR2, TLR3 and TLR4 are responsible for 
recognizing C. pneumoniae and initiating the proinflammatory signaling cascades [146]. 
The myeloid differentiation factor 88 (MyD88) is an adaptor protein that is involved in 
most TLR signaling cascades, and it has been reported to also take part in C. 
pneumoniae-induced TLR signaling [133, 141, 242, 243], while MyD88 independent 
signaling is also reported [133]. 
When TLRs get activated by the pathogen, they initiate the inflammation signaling 
cascade involving mitogen-activated protein kinases (MAPKs) [244] and it has been 
reported that C. pneumoniae also induces MAPK activation [245]. There are three main 
MAPKs that differentially regulate the inflammatory reactions: the extracellular signal-
regulated protein kinase (ERK), the p38 MAP kinase (p38) and the c-Jun amino-terminal 
kinase (JNK) and they can be activated with different signaling molecules and stimuli, 
which are cell type-dependent [246, 247]. All three major MAPKs have been reported 
to be activated in C. pneumoniae infection [248]. On the other hand, Cheng et al. [149] 
reported that C. pneumoniae infection induced the phosphorylation of ERK, JNK1/2 and 
p38 MAPKs, but a p38 inhibitor did not inhibit the further signaling cascade.  
In addition to pathogens, the activation of the MAPK signaling may occur as a response 
to reactive oxygen species (ROS) [249] that cause oxidative stress. Oxidative stress, i.e. 
the excess amount of oxidants, ROS and reactive nitrogen species (RNS) in the cells 
leads to various cellular dysfunctions and the initiation of inflammation, but also to the 
activation of the innate immune system [250]. Oxidative stress has also been related to 
C. pneumoniae infection in various ways [251]. On one hand, C. pneumoniae is reported 
to increase the levels of ROS and RNS in the cells, which is a mechanism of the cells to 
fight the intruders [95, 102]. On the other hand, C. pneumoniae is able to survive in that 
oxidative environment, which might induce their persistent form and thus facilitate their 
prolonged survival in the host cells [97].  
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ROS production in THP-1 cells was measured in this work, and both LPS and C. 
pneumoniae infection induced the intracellular ROS levels in these cells after 48 h 
exposure (Figure 7). The impact of schisandrin, schisandrin B and schisandrin C was 
detected on basal as well as LPS- and C. pneumoniae-induced ROS levels. Schisandrin 
elevated the basal ROS levels already at a 1-h exposure in THP-1 monocytes (Figure 
8A), whereas schisandrin and schisandrin C did so after a longer, 24–72-h exposure in 
THP-1 macrophages (Figure 8B). Interestingly, the concomitant infection/LPS exposure 
reversed this lignan-induced elevation in naïve cells, and schisandrin B even decreased 
the ROS levels in LPS- (Figure 9A) and C. pneumoniae-stimulated samples (Figure 9B). 
Schisandrin C caused a similar decrease in ROS only in LPS-induces samples (Figure 
9A). Of note, schisandrin B decreased the THP-1 macrophage cell viability significantly 
(Table 8), which may have an impact on these results. 
The ROS levels, as detected by the DCFH-DA method, represent the total ROS amount 
in the cells. It remains unknown whether these ROS are produced in the mitochondrial 
respiratory chain or in the cytoplasm e.g. via NADPH oxidase, and further studies should 
be carried out in the future to elucidate the mechanisms of the observed ROS alterations. 
Nitric oxide (NO) is one of the molecules related to C. pneumoniae-host cell interaction 
[97]. NO functions as a signaling molecule, and it plays an important role in host defense 
against bacterial infections [252]. NO itself is not particularly reactive, but more reactive 
nitrogen molecules, namely peroxynitrite (ONOO-), nitrogen dioxide (NO2) and nitrogen 
trioxide (N2O3) are produced upon its reaction with oxygen or superoxide. NO is 
produced by two different enzymes, endothelial nitric oxide synthetase (eNOS), which 
is constitutively producing NO maintaining the normal functions in the cells, such as 
vasodilation and proliferation, and inducible NOS (iNOS), which is expressed e.g. in 
macrophages in response to inflammation and cytokine release [253]. C. pneumoniae 
has been reported to induce NO production via iNOS, which leads to oxidative stress 
and thus inflammation in the cells [101, 254]. The results in this work demonstrate that 
both LPS (Figure 6A) and C. pneumoniae (Figure 6B) exposure elevate the levels of 
nitrate, the metabolite of NO, in RAW267.4 cells, but no elevation after several attempts 
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was observed in THP-1 cells. There have been some controversial results of this matter, 
but several studies support our findings that NO is not produced in THP-1 cells [233, 
255]. In general, conflicting evidence of the production of NO in human PBMC has been 
presented among the studies [256]. These results imply that there are cell type- and 
species-specific differences in the production of NO after bacterial exposure, which 
further translates into differential inflammatory reactions. The impact of schisandrin and 
schisandrin B on LPS- (Figure 6A) and C. pneumoniae-induced (Figure 6B) NO levels 
were also studied in RAW264.7 macrophages. The results showed that schisandrin B, 
but not schisandrin, decreased both the LPS- and C. pneumoniae-induced NO levels 
significantly. These results suggest that schisandrin B alleviates the infection-induced 
inflammatory response in murine macrophages, at least by decreasing NO levels. The 
potential clinical relevance of this effect in C. pneumoniae infection in humans is 
uncertain due to the species-specific differences in NO production. NO, however, is 
produced by other human cells, such as epithelial and endothelial cells [257] and the 
effect of schisandrin lignans on C. pneumoniae-induced NO production in those cells 
should be studied further. 
The effects of schisandrin lignans on the oxidative state in cells have been widely 
studied. There are several studies suggesting the increase of intracellular ROS/RNS by 
schisandrin lignans [219, 222, 258-260], while other studies report no such impact [203], 
or even opposing effects [261-263]. It seems that the nature of impact schisandrin lignans 
are exerting on the cellular redox state is strongly dependent on the cell type and the way 
the cells are stimulated/treated, and the mechanisms of action may also vary. In murine 
models, the effect of schisandrin B on the cellular redox balance has been suggested to 
occur via the inhibition of nuclear factor-erythroid 2-related factor 2 (Nrf2), which 
induces the production of antioxidative enzymes and further leads to inhibition of NF-
κB function [219]. 
NF-κB is a transcription factor that regulates the gene expression involving 
inflammatory functions, such as that of the cytokines IL-1, IL-6, IL-8 and IL-12 [264]. 
The NF-κB activation is also considered as one of the hallmarks of chronic inflammatory 
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diseases [264]. It has been shown to have a major role in atherogenesis by regulating the 
transcription of inflammatory genes, cell proliferation, and apoptosis. NF-κB has been 
found to be activated in atheromatous, but not in healthy arteries [265]. C. pneumoniae 
infection also affects the NF-κB function via the TLR2/4-MAPK signaling pathway 
[139, 148]. The association of schisandrin lignans and C. pneumoniae with NF-κB could 
be one of the mechanisms leading to the alteration of ROS levels. However, confirming 
this hypothesis is beyond the scope of this work and will instead be the subject of a future 
project. 
In this study, we examined whether THP-1 monocytes produced cytokines after LPS 
administration or C. pneumoniae infection. This cell line was found to secrete IL-6 and 
IL-12 after LPS exposure, but only IL-12 after C. pneumoniae infection, and the 
concentration was remarkably lower than that seen in the LPS-exposed cells. It is known 
that LPS of C. pneumoniae is not as immunogenic as LPS of other gram-negative 
bacteria [266], so these kinds of results were as expected and only confirmed the pre-
made assumptions, about the different immunogenicity of E. coli and C. pneumoniae. 
There may be several factors explaining such low or absent cytokine levels in our 
experiments when compared to previously reported studies (Table 2). Firstly, the 
exposure to C. pneumoniae has been conducted differentially in the experiments. 
Mamata et al. [91], for example, used a MOI of 10 in their experiments, whereas we 
infected at a more moderate dose at MOI2. These authors also used a different strain of 
the bacterium, TW-183, in place of the K7 used in our studies, which could also result 
in a dramatically different immune response. Zhou et al. [93] studied the impact of 
isolated chlamydial Hsp10 protein on host cells, whereas all our experiments were 
conducted using whole bacterial infections. The more complete host-pathogen interplay 
captured in our data may also translate into contradictory results. Schisandrin lignans 
influenced inflammatory cytokine production (Figure 5) in both LPS- and C. 
pneumoniae-induced cells. We showed that schisandrin B and schisandrin C reduce the 
IL-6 and IL-12 production in THP-1 monocytes. This reduction may occur via the 
inhibition of the NF-κB function through the transcription factor Nrf2, but further 
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experiments must be conducted to verify this hypothesis. PPARγ is also known to 
suppress the NF-κB [130], and schisandrin B and schisandrin C might have inhibited the 
NF-κB function by inducing the PPARγ transcription (Table 10). Our gene expression 
analysis was carried out in murine cells, which should be taken into account when 
comparing the results gained from human cells. There are studies reporting the impact 
of schisandrin lignans on the production of inflammatory cytokines, namely IL-1β, IL-
4, IL-6 and TNF-α, but most of these have been conducted in rodent models [219, 220] 
and only a few in human cell lines [267]. Our results provide novel information about 
the effects of schisandrin lignans in human cells and support the hypothesis that these 
lignans can alleviate the inflammatory response in human immune cells. 
NF-κB has been reported to be involved in inflammasome activation [268]. 
Inflammasomes are protein complexes that activate caspases, which further activate 
inflammatory cytokine production. Inflammasomes are part of the innate immune 
system and play a significant role in defense against pathogens [269]. Nucleotide-
binding oligomerization domain-like receptor protein 3 (NLRP3) is the most widely 
studied inflammasome and its mechanism of action is well characterized. The activation 
of inflammasomes is a two-step process. First, in NLRP3 priming, the transcription of 
the inflammasome components caspase-1 and pro-IL-18 is upregulated, which occurs 
through different stimuli of cellular stress, e.g. by PAMPs that activate TLRs, further 
leading to NF-κB activation. ROS are also reported to be an important factor in activating 
the NLPR3 inflammasome [270]. Mitochondrial dysfunction and, consequently, 
mitochondrial ROS (mtROS) production are also playing a role in NLRP3 activation 
[271]. In addition to ROS, the regulator of antioxidant gene expression Nrf2 is known to 
take part in the activation of the NLRP3 inflammasome. On one hand, Nrf2 expression 
can downregulate the NLRP3 activation by reducing NF-κB function, and through that 
the expression of NLRP3, Caspase-1 and IL-18 (the components of NLRP3 
inflammasome) is also downregulated [272]. On the other hand, Nrf2 expression is 
reported to be necessary for inflammasome activation [273]. 
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C. pneumoniae infection has also been reported to activate the NLRP3 inflammasome 
[274]. It has been shown that C. pneumoniae increases IL-1β production, which requires 
the NLRP3 inflammasome activation in murine macrophages [275, 276]. In addition, C. 
pneumoniae growth has been shown to be reduced without NLPR3 inflammasome 
activation [274], implying that it is beneficial for the bacteria. Studies have also showed 
that lipid accumulation is related to NLRP3 inflammasome activation and the following 
inhibition of ABCA1-mediated cholesterol efflux [276].  
Schisandrin lignans are known to activate Nrf2 and, through that, the NF- κB function 
is reduced [219]. Nrf2 has also been reported to inhibit NLRP3 activation and IL-1β 
production [272]. Indeed, schisandrin B has been demonstrated to suppress the NLRP3 
inflammasome through Nrf2 expression [277]. Thus, one mechanism by which 
schisandrin B and schisandrin C alleviate the C. pneumoniae-induced inflammatory 
effects in host cells could be by inhibiting NLRP3 inflammasome activation through 
Nrf2 and NF-κB. This may in turn lead to ameliorated inflammatory reaction, which 
could also result in the inhibition of lipid accumulation and thus the reduction of foam 
cell formation also observed in this study. 
         
 
Figure 15. The possible signaling pathway involved in the activity of schisandrin lignans 
in macrophages, leading to alleviation of inflammation and atheroma formation. 
Schisandrin lignans activate Nrf2 and PPARγ, which suppresses the NF-κB signaling 
and that leads to the downregulation of the inflammatory cytokine production, NLRP3 
activation and ROS production. This alleviates the oxidative stress and consequently 




In addition to NF-κB, another transcription factor that is regulated by C. pneumoniae 
infection is PPARγ. PPARγ is a nuclear receptor, which regulates the lipid and glucose 
metabolism as well as immune responses in the cells [127]. C. pneumoniae affects 
PPARγ activation via the MAPK pathway [149] which leads to alterations in cellular 
lipid metabolism. PPARγ is also associated with glutathione metabolism in the cells 
[278, 279], which is required for the regulation of cellular oxidative state. In turn, this is 
reflected to lipid metabolism and the overall inflammation status. 
The glutathione (GSH) system is one of the main regulators of oxidative homeostasis in 
the cells. GSH is synthetized by two reactions catalyzed by glutamate-cysteine ligase 
(GCL) and GSH synthetase (GS) [103]. First, GCL forms γ-glutamylcysteine from 
glutamate and cysteine, which is the rate limiting step in GSH synthesis and depends on 
the availability of cysteine. GCL contains two subunits, a catalytic subunit, GCLc, and 
a modifier subunit, GCLm. In addition to the depletion of cysteine, the synthesis rate is 
also inhibited by a feedback mechanism by GSH. The other reaction in GSH synthesis 
is the condensation of γ-glutamylcysteine and glycine, which is catalyzed by GS.  
Various cellular factors regulate GSH synthesis via GCL activity, e.g. oxidative stress, 
NF-κB activity, inflammatory cytokines and NO production [103]. One important 
regulator of the GSH synthesis rate is the activation of γ-glytamyltranspeptidase (GGT-
1), which is the only enzyme that can break down GSH [280]. GGT-1 is located on the 
outer cell membrane where it breaks down GSH to γ-glutamyl compounds and 
cysteinylglycine, which is further cleaved into amino acids. These amino acids, 
including cysteine, are then taken back into the cells and used in GSH synthesis, thus 
making GGT-1 a critical component of the cellular GSH homeostasis. 
Oxidative stress is expected to decrease the levels of GSH because it is used to scavenge 
the oxidants from the cells. The decrease in overall GSH leads to the upregulation of its 
synthesis: GGT-1 levels become elevated, which increases the extracellular GSH 




On a systemic level, GSH can be transported between the tissues where it is needed to 
counteract oxidative stress or exert other effects. The GSH is then exported out from the 
cells, broken down by GGT-1, and transferred wherever the components are needed for 
GSH synthesis [281]. 
In this work, the impact of C. pneumoniae infection on GSH levels in THP-1 
macrophages was studied. The infection increased the cellular GSH levels at 48 and 72 
h of incubation. In previous reports, C. pneumoniae has been shown to reduce the GSH 
levels in RAW264.7 [99] and human T cells [114], but no data were available from the 
THP-1 cell line. The results from this work, together with previous findings, suggest that 
the impact of C. pneumoniae infection on cellular GSH levels are species- and cell type 
specific.  
In addition, the impact of schisandrin, schisandrin B and schisandrin C on basal 
intracellular GSH was studied in both monocytic and macrophage-like THP-1 cells as 
well as in RAW264.7. Interestingly, the results were markedly different between the 
human and murine cell lines (Figure 10). In human THP-1 monocytes and macrophages, 
schisandrin B and schisandrin C decreased the total GSH levels at all time points, 
whereas in RAW264.7 macrophages schisandrin B and schisandrin C elevated the total 
GSH levels, and schisandrin decreased the levels after 72 h incubation. These results 
further support the finding that there are species-specific differences in the GSH 
signaling cascade between mice and humans. Furthermore, they demonstrate that 
schisandrin lignans cause different, even opposite results between different cell lines, 
which is an important factor to consider in the interpretation of other studies on these 
compounds. The sensitivity of cells towards these studied schisandrin lignans also varies 
between the cell lines (Table 8). Schisandrin and schisandrin C are well tolerated by cells 
used in these studies, but schisandrin B decreases the viability of THP-1 macrophages 
and RAW264.7 macrophages with high concentration and long incubation time.  
We also examined whether schisandrin lignans affected the expression of genes involved 
in the GSH metabolism in RAW264.7 cells. The transcription levels of GCLc, GCLm, 
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and GGT-1 were determined. Schisandrin B was shown to cause the upregulation of each 
of these genes (Table 10), which implies that GSH synthesis was increased in schisandrin 
B-treated cells, a finding that is in line with the observed elevation of the total GSH 
levels (Figure 10). Interestingly, only the transcription of GCLm was changed in 
schisandrin C-treated cells. This could mean that the observed protein levels arise from 
post-transcriptional control. Moreover, the finding implies that schisandrin B and C may 
have different mechanisms for the alteration of cellular GSH levels. The gene expression 
profile in THP-1 cells would be an interesting subject for a future study, since the impact 
of schisandrin lignans on GSH levels in THP-1 cells were opposite to the ones seen in 
RAW264.7 macrophages. 
Oxidative stress is a major pathological mechanism in the development of 
atherosclerosis [282]. Atheroma formation begins when macrophages accumulate lipids 
within their cytoplasm and thus become foam cells. The foam cells then gather in the 
arterial walls and attract other cells and components, which further enhances the 
atheroma formation [283]. Lipid oxidization is a crucial step in foam cell formation [282] 
and intracellular ROS are involved in the signaling pathways induced by the recognition 
and internalization of oxidized LDL [284].  
We studied the foam cell formation in THP-1 and RAW264.7 macrophages, and C. 
pneumoniae in the presence of LDL was shown to clearly promote lipid accumulation in 
both cells lines (Figure 12). There are several studies reporting the foam cell formation 
after C. pneumoniae infection in human macrophages [134, 137, 138, 140], mouse 
macrophages [131-133] and also in in vivo animal models [141, 276]. In this study, gene 
expression analyses were conducted to investigate the possible mechanisms related to C. 
pneumoniae-induced lipid accumulation in RAW264.7 cells. When the transcription of 
genes related to lipid metabolism (PPARγ, a transcription factor; CD36, scavenger 
receptor; ABCA1, cholesterol efflux protein) during C. pneumoniae infection was 
quantified, the transcription of PPARγ was observed to be significantly reduced (Table 
9). A similar C. pneumoniae-induced PPARγ reduction has previously been reported in 
THP-1 cells [140] but no data have been available in RAW264.7 macrophages. 
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According to these data, it seems that C. pneumoniae-stimulated foam cell formation in 
RAW264.7 macrophages is associated with PPARγ downregulation. 
The impact of schisandrin lignans on RAW264.7 and THP-1 foam cell formation and 
their ability to alter the gene expression in RAW264.7 cells, concerning lipid 
metabolism, were also studied. Schisandrin had no effect on lipid accumulation in either 
cell line (Figure 12), but schisandrin B and schisandrin C reduced it, thus inhibiting foam 
cell formation in both. It is of note, however, that the lipid accumulation was only 
observed by microscopy and not quantified by other methods. Both schisandrin B and C 
also showed a tendency to suppress the degree of cholesterol esterification in RAW264.7 
macrophages (Fig 13). 
The gene expression analyses demonstrated that schisandrin B and schisandrin C 
induced the PPARγ transcription in RAW264.7 cells (Table 10), which can be one 
mechanism behind the alleviation of lipid accumulation as shown in Figure 12. 
Schisandrin, instead, had no effect on the PPARγ transcription and it also did not inhibit 
the foam cell formation, providing further evidence for this association. We also 
examined whether foam cell formation inhibition by schisandrin B and C could occur 
due to the expression of genes involved in lipid uptake (CD36) or lipid efflux (ABCA1) 
(Table 10). There were no statistically significant changes in CD36 transcription after 
treatment with the lignans. Even though CD36 has been reported to be important in 
oxidized LDL uptake, its role in atherogenesis is controversial [285]. Another scavenger 
receptor, lectin-like oxLDL receptor-1 (LOX-1), is also known to take part in oxidized 
LDL uptake [282] and further studies on its role in the impact of schisandrin lignans on 
foam cell formation might shed more light on the question. On the other hand, the CD36 
regulation may also occur on the translational level, which could explain its unaltered 
gene expression. Indeed, although it has been reported that CD36 transcription is induced 
via a PPARγ-dependent manner [286], other studies suggest that PPARγ activation is 
not needed for CD36 upregulation [287]. 
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The transcription of the cholesterol efflux pump gene, ABCA1 was significantly affected 
by treatment with the schisandrin lignans. Schisandrin downregulated ACBA1 
transcription (Table 10), indicating that lipid efflux was decreased in the cells. This may 
result in increased lipid accumulation, but the matter requires further investigation. 
Schisandrin B and schisandrin C, instead, upregulated ABCA1, indicating that lipid 
efflux may have been increased in the cells, which could explain the observed reduction 
in foam cell formation. In the foam cell studies, the impact of MAPK inhibitors on the 
lipid accumulation of RAW264.7 and THP-1 cells was also determined. The JNK 
inhibitor SP600125 prevented the lipid accumulation in RAW264.7 cells (Figure 12A) 
but not in THP-1 cells (Figure 12B), whereas the p38 inhibitor SB203580 seemed to 
reduce the lipid accumulation in THP-1 cells. These results are in line with previous 
observations that the foam cell formation occurs via the MAPK pathway [132, 147, 149], 
and further imply that there are cell-type or species-specific differences in the kinases 
involved in the process. The impact of GSH synthesis inhibitor BSO on foam cell 
formation in RAW264.7 cells was also studied, and it was shown to induce lipid 
accumulation in these cells (Figure 12A). This implies that the GSH concentration in the 
cells is strongly associated with foam cell formation in RAW264.7, which has also been 
suggested in previous studies [234]. One possible mechanism for the schisandrin B and 
schisandrin C-mediated elevation of the GSH concentration could be the induction of 
GSH synthesis and the resulting alleviation of the oxidative stress in the cells. In THP-1 
cells, the mechanisms concerning the alteration of GSH levels and foam cell formation 
seems to differ from that in RAW264.7 macrophages, since the schisandrin lignans 
reduced the cellular GSH levels but still seemed to inhibit foam cell formation. 
Monocytes and macrophages are key mediators of chlamydial infection and its 
contribution to various chronic inflammatory diseases. One of the most efficient ways to 
decrease C. pneumoniae-related infection burden in chronic inflammatory diseases 
would be to block the transfer of bacteria from lung epithelium to phagocytes, which 
would eliminate the possibility of the bacteria to initiate the inflammatory processes 
leading to diseases such as atherosclerosis. In one of the studies included in this thesis, 
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a novel platform was established for studying the transfer of C. pneumoniae from 
epithelial HL cells to THP-1 monocytes. The method is based on the efficient separation 
of THP-1 cells from previously infected HL cells after their coculture, followed by the 
quantification of C. pneumoniae genome numbers in the THP-1. Despite the well-
described role of systemic C. pneumoniae dissemination in chronic inflammatory 
diseases, there is a very limited amount of studies demonstrating the use of coculture 
models in Chlamydia research. U937 monocytes have been cultured together with 
infected human arterial endothelial cells (HMECs) [288], human umbilical vein 
endothelial cells (HUVECs) and coronary artery smooth muscle cells (CASMCs) [289]. 
These studies reported that C. pneumoniae is able to transfer from monocytes to HMECs 
and CASMCs. However, these studies concern a later stage of systemic C. pneumoniae 
dissemination, in which bacteria have already transferred from the respiratory tract to 
monocytes and were then further transferring to the vasculature. Before this work, no 
studies of C. pneumoniae transfer from epithelial cells to phagocytes were available. 
C. pneumoniae has been reported to activate the MAPK signaling pathway in the cells 
[248, 290], and this pathway is important e.g. in the internalization and exit of the 
bacteria [40, 291]. C. pneumoniae is thought to activate the MAPK pathway through 
TLR binding. When TLRs recognize C. pneumoniae, the JNK, ERK and p38 kinases are 
phosphorylated and activated immediately [248]. MAPK signaling activates actin 
polymerization and remodeling at the site of C. pneumoniae entry, which enables the 
successful internalization of the bacteria [291]. This is also supported by the finding that 
the blockage of MAPK signaling decreases C. pneumoniae internalization in epithelial 
cells [40]. Besides the TLR-mediated MAPK activation, another factor related to actin 
remodeling and C. pneumoniae internalization is the chlamydial protein Tarp [56]. It has 
been reported to be involved in MAPK signaling activation [292], and Tarp might thus 
be one means of C. pneumoniae to induce actin remodeling. 
While optimizing the coculture model, the MAPK inhibitors, SP600125 (JNK), 
SB203580 (p38) and FR180204 (ERK) were studied as possible positive controls to be 
used in the assay. All three MAPK inhibitors inhibited the C. pneumoniae transfer 
92 
 
between the epithelial cells and monocytes (Figure 13). In several follow-up studies, we 
investigated at which point of the transfer the MAPK inhibitors might be interfering. Our 
results show that the JNK inhibitor (SP600125) and p38 inhibitor (SB203580) were able 
to significantly inhibit the C. pneumoniae internalization (Figure 14). The ERK inhibitor 
also reduced internalization, but the change did not reach statistical significance. Actin 
polymerization is also necessary in one of the exiting mechanisms of Chlamydia, 
extrusion. When newly-formed EBs inside the host cells are ready to exit, actin is 
polymerized and recruited to form a coat around the bacteria, which enables the inclusion 
to bud out from the cells leaving the host cell intact [293]. The impact of MAPK 
inhibitors on C. pneumoniae exit could be one possible mechanism by which they block 
the transfer. Although there was no reduction in EB release from the HL epithelial cells 
with any of the studied MAPK inhibitors (Figure 14), the JNK inhibitor was shown to 
induce the EB exit. This is an interesting result and should be examined in further studies. 
These results also demonstrate that there were no changes in either the EB production in 
HL cells or the EB infectivity after MAPK treatment. Taken together, these results show 
that MAPK inhibitors can be used as positive controls in the studies of C. pneumoniae 
transfer using the described novel method. The overall impact of MAPK inhibitors on 
C. pneumoniae transfer remains unknown, with one identified mechanism being their 
ability to block the internalization of bacteria into THP-1 cells. This novel platform 
provides new opportunities for further profiling studies of schisandrin lignans as well as 






In this work, monocyte and macrophage cell lines were used in C. pneumoniae infections 
to establish cell models harboring persistent chlamydial infection. The impact of 
antichlamydial dibenzocyclooctadiene lignans schisandrin, schisandrin B and 
schisandrin C was evaluated on the C. pneumoniae-induced inflammatory functions in 
these cell lines. These studies showed that C. pneumoniae modifies the normal functions 
of these innate immune system cells. A varying activity of the studied lignans on these 
inflammatory functions was additionally demonstrated. 
While C. pneumoniae infection initiated the inflammatory functions of the cells, 
including inflammatory cytokine production, redox balance alteration and foam cell 
formation, schisandrin B and schisandrin C showed an alleviating action against all of 
those cellular functions. Of the three studied lignans, schisandrin was least effective 
against C. pneumoniae-induced inflammatory functions. 
Differential responses between human THP-1 and murine RAW264.7 cell lines were 
observed concerning both the C. pneumoniae infection and the schisandrin lignan 
treatment, implying species-specific differences in the innate immune system. There was 
no NO production recorded in THP-1 cells in our studies, but the NO levels in 
RAW264.7 were significantly elevated during C. pneumoniae infection. The GSH 
signaling pathways also seem to act differently between the cell lines, since the 
schisandrin lignan treatment resulted in opposing responses. In addition, the MAPK 
signaling pathways seem to activate differently between the cell lines. In the foam cell 
studies, the JNK inhibitor only blocked the lipid accumulation in RAW264.7 cells and 
not in THP-1 cells, while the p38 inhibitor showed activity in THP-1 cells. Considering 
these differences, it may be advisable to prioritize the use of human cell lines in the C. 
pneumoniae studies aimed for the development of new antichlamydial lead compounds. 
The overall aim behind the studies in this work, conducted with schisandrin lignans in 
innate immune system cells, was the profiling of the compounds against persistent C. 
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pneumoniae infection. In addition to the eradication of C. pneumoniae from the tissues 
and diminishing its inflammatory functions, blocking the transfer of the bacteria from 
respiratory tract epithelium to phagocytes could be a putative mechanism to fight the 
chlamydial persistence. In this thesis, I introduced a novel platform for studying the C. 
pneumoniae transfer between the cells, which could be added to the compound profiling 
workflow of antichlamydial compounds. 
Both in vitro and in vivo studies of absorption, distribution, metabolism and excretion 
should be conducted with schisandrin lignans, as well as in vivo toxicity studies. If the 
results from those will be satisfactory, clinical trials may be planned and the drug 
development of these natural compounds continued. 
The results presented in this thesis have provided a lot of new information about 
schisandrin lignans and their mechanisms against C. pneumoniae-induced inflammatory 
functions and atheroma progression. Altogether, these studies have highlighted the 
potential of schisandrin lignans as antichlamydial compounds and increased the 
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